{"questions": [{"id": "5a75eb6483b0d9ea66000004", "body": "What is Blount's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19370370", "http://www.ncbi.nlm.nih.gov/pubmed/20609637", "http://www.ncbi.nlm.nih.gov/pubmed/25932193", "http://www.ncbi.nlm.nih.gov/pubmed/15481748", "http://www.ncbi.nlm.nih.gov/pubmed/27583129", "http://www.ncbi.nlm.nih.gov/pubmed/12077670", "http://www.ncbi.nlm.nih.gov/pubmed/8657465", "http://www.ncbi.nlm.nih.gov/pubmed/23610758", "http://www.ncbi.nlm.nih.gov/pubmed/7670990", "http://www.ncbi.nlm.nih.gov/pubmed/9702674"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Correction of Blount's disease by a multi-axial external fixation system.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19370370"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "BACKGROUND: Blount's disease is a multi-planar deformity affecting the pediatric population which leads to varus alignment of the lower extremities.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19370370"}, {"offsetInBeginSection": 426, "offsetInEndSection": 562, "text": "The purpose of this study was to determine the efficacy of the MAC system for the treatment of pediatric patients with Blount's disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19370370"}, {"offsetInBeginSection": 562, "offsetInEndSection": 738, "text": "METHODS: A retrospective analysis of 17 consecutive patients with surgically corrected Blount's disease using the MAC system with tibial and fibular osteotomies was identified.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19370370"}, {"offsetInBeginSection": 1180, "offsetInEndSection": 1315, "text": "RESULTS: The MAC system was able to correct the deformity of Blount's disease as measured by a decrease in the MAD (40.2 +/- 29.3 mm; P", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19370370"}, {"offsetInBeginSection": 1316, "offsetInEndSection": 1566, "text": "CONCLUSIONS: Correction of Blount's disease with osteotomy of the tibia and fibula as well as dynamic fixation with the MAC system achieved deformity correction as measured by radiographic indices with minimal intra- and post-operative complications.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19370370"}, {"offsetInBeginSection": 1567, "offsetInEndSection": 1688, "text": "The ease of application and adjustment of the MAC system makes it an attractive option for Blount's deformity correction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19370370"}, {"offsetInBeginSection": 0, "offsetInEndSection": 40, "text": "Can Blount's disease heal spontaneously?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20609637"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "INTRODUCTION: In stage\u00a01 of all currently accepted classifications for infantile tibia vara, the diagnosis is difficult between physiological bowing and true Blount's disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20609637"}, {"offsetInBeginSection": 268, "offsetInEndSection": 477, "text": "METHODS: We retrospectively studied a series of 26 patients born in the Indian Ocean area, presenting at stage\u00a01 of the disease, in order to determine whether any of them were likely to heal without treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20609637"}]}, {"id": "5a6a2dcab750ff4455000023", "body": "Which are the constitutive parts of a Genomic Regulatory Block (GRB)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22666536", "http://www.ncbi.nlm.nih.gov/pubmed/17387144", "http://www.ncbi.nlm.nih.gov/pubmed/19374772", "http://www.ncbi.nlm.nih.gov/pubmed/22962458", "http://www.ncbi.nlm.nih.gov/pubmed/21619633", "http://www.ncbi.nlm.nih.gov/pubmed/22234889", "http://www.ncbi.nlm.nih.gov/pubmed/17989259"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Comparative genomics of the Hedgehog loci in chordates and the origins of Shh regulatory novelties.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22666536"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "The origin and evolution of the complex regulatory landscapes of some vertebrate developmental genes, often spanning hundreds of Kbp and including neighboring genes, remain poorly understood.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22666536"}, {"offsetInBeginSection": 192, "offsetInEndSection": 436, "text": "The Sonic Hedgehog (Shh) genomic regulatory block (GRB) is one of the best functionally characterized examples, with several discrete enhancers reported within its introns, vast upstream gene-free region and neighboring genes (Lmbr1 and Rnf32).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22666536"}, {"offsetInBeginSection": 437, "offsetInEndSection": 650, "text": "To investigate the origin and evolution of this GRB, we sequenced and characterized the Hedgehog (Hh) loci from three invertebrate chordate amphioxus species, which share several early expression domains with Shh.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22666536"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Genomic regulatory blocks encompass multiple neighboring genes and maintain conserved synteny in vertebrates.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17387144"}, {"offsetInBeginSection": 114, "offsetInEndSection": 354, "text": "We found the largest mammal-teleost conserved chromosomal segments to be spanned by highly conserved noncoding elements (HCNEs), their developmental regulatory target genes, and phylogenetically and functionally unrelated \"bystander\" genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17387144"}, {"offsetInBeginSection": 355, "offsetInEndSection": 545, "text": "Bystander genes are not specifically under the control of the regulatory elements that drive the target genes and are expressed in patterns that are different from those of the target genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17387144"}, {"offsetInBeginSection": 546, "offsetInEndSection": 915, "text": "Reporter insertions distal to zebrafish developmental regulatory genes pax6.1/2, rx3, id1, and fgf8 and miRNA genes mirn9-1 and mirn9-5 recapitulate the expression patterns of these genes even if located inside or beyond bystander genes, suggesting that the regulatory domain of a developmental regulatory gene can extend into and beyond adjacent transcriptional units.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17387144"}, {"offsetInBeginSection": 916, "offsetInEndSection": 986, "text": "We termed these chromosomal segments genomic regulatory blocks (GRBs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17387144"}, {"offsetInBeginSection": 987, "offsetInEndSection": 1275, "text": "After whole genome duplication in teleosts, GRBs, including HCNEs and target genes, were often maintained in both copies, while bystander genes were typically lost from one GRB, strongly suggesting that evolutionary pressure acts to keep the single-copy GRBs of higher vertebrates intact.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17387144"}]}, {"id": "5a735cdc3b9d13c708000004", "body": "In November 2017,  in what phase  was  the clinical trial for the drug SYL040012?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24025752"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Phase I clinical trial of SYL040012, a small interfering RNA targeting \u03b2-adrenergic receptor 2, for lowering intraocular pressure.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752"}, {"offsetInBeginSection": 0, "offsetInEndSection": 195, "text": "The objective of this study was to evaluate ocular tolerance, safety, and effect on intraocular pressure (IOP) of a topically administered small interfering RNA; SYL040012, on healthy volunteers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752"}]}, {"id": "5a777ab9faa1ab7d2e00000a", "body": "What is the drug target(s) for Belsomra?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25336862"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "Idelalisib (Zydelig) for certain types of leukemia and lymphoma, peginterferon beta-1a (Plegridy) for relapsing forms of multiple sclerosis, and suvorexant (Belsomra) for insomnia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25336862"}]}, {"id": "5a8861eb8cb19eca6b000001", "body": "List the two most important synaptic markers.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22206847", "http://www.ncbi.nlm.nih.gov/pubmed/24205365", "http://www.ncbi.nlm.nih.gov/pubmed/27906174", "http://www.ncbi.nlm.nih.gov/pubmed/25755633", "http://www.ncbi.nlm.nih.gov/pubmed/26017624", "http://www.ncbi.nlm.nih.gov/pubmed/26776762", "http://www.ncbi.nlm.nih.gov/pubmed/22609570", "http://www.ncbi.nlm.nih.gov/pubmed/7783952", "http://www.ncbi.nlm.nih.gov/pubmed/21074556", "http://www.ncbi.nlm.nih.gov/pubmed/20540992"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Synaptic protein deficits are associated with dementia irrespective of extreme old age.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22206847"}, {"offsetInBeginSection": 205, "offsetInEndSection": 431, "text": "The levels and distributions of some synaptic proteins have been found to be associated with dementia severity, even in the oldest-old, but the molecular and functional nature of these deficits have not been studied in detail.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22206847"}, {"offsetInBeginSection": 432, "offsetInEndSection": 659, "text": "The objective of this study was to assess the relationship of dementia with gene and protein expression of a panel of synaptic markers associated with different synaptic functions in young-, middle-, and oldest-old individuals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22206847"}, {"offsetInBeginSection": 660, "offsetInEndSection": 957, "text": "The protein and messenger RNA (mRNA) levels of 7 synaptic markers (complexin-1, complexin-2, synaptophysin, synaptobrevin, syntaxin, synaptosomal-associated protein 25 (SNAP-25), and septin-5) were compared in the brains of nondemented and demented individuals ranging from 70 to 103 years of age.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22206847"}, {"offsetInBeginSection": 1258, "offsetInEndSection": 1400, "text": "The brains of persons with dementia evidenced significantly lower levels of gene and protein expression of synaptic markers regardless of age.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22206847"}, {"offsetInBeginSection": 1401, "offsetInEndSection": 1538, "text": "Importantly, dementia was associated with reductions in all measured synaptic markers irrespective of their role(s) in synaptic function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22206847"}, {"offsetInBeginSection": 1539, "offsetInEndSection": 1846, "text": "Although other dementia-associated hallmarks of AD neuropathology (neuritic plaques and neurofibrillary tangles) become less prominent with increasing age, synaptic marker abnormalities in dementia remain constant with increasing age and may represent an independent substrate of dementia spanning all ages.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22206847"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Acute physiological stress promotes clustering of synaptic markers and alters spine morphology in the hippocampus.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24205365"}, {"offsetInBeginSection": 196, "offsetInEndSection": 453, "text": "Here we investigated these synaptic markers in the context of an acute 1h platform stress, which can disrupt spatial memory retrieval for a short-term memory on the object placement task and long-term memory retrieval on a well-learned radial arm maze task.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24205365"}, {"offsetInBeginSection": 454, "offsetInEndSection": 575, "text": "Acute stress increased serum corticosterone and elevated the expression of synaptic PKM\u03b6 while decreasing synaptic GluA2.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24205365"}]}, {"id": "5a75ee7e83b0d9ea66000005", "body": "List symptoms of the Zieve's syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7110955", "http://www.ncbi.nlm.nih.gov/pubmed/2616809", "http://www.ncbi.nlm.nih.gov/pubmed/464793", "http://www.ncbi.nlm.nih.gov/pubmed/26203455", "http://www.ncbi.nlm.nih.gov/pubmed/548954", "http://www.ncbi.nlm.nih.gov/pubmed/11761804", "http://www.ncbi.nlm.nih.gov/pubmed/8819039", "http://www.ncbi.nlm.nih.gov/pubmed/966632"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "[Zieve's syndrome and acute alcoholic hepatitis (author's transl)].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7110955"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "Zieve's syndrome, characterized by jaundice, hyperlipaemia and haemolytic anaemia, usually develops in young, chronically alcoholic subjects with enlarged fatty liver.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7110955"}, {"offsetInBeginSection": 508, "offsetInEndSection": 638, "text": "Zieve's syndrome therefore is not benign but precedes acute alcoholic hepatitis episodes on a normal, fibrotic or cirrhotic liver.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7110955"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "[Pathomechanism of Zieve's syndrome--observation of patients treated at the Infectious Disease Clinic, Medical Academy, in Bydgoszcz].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2616809"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "The views are presented on the pathological mechanism of Zieve's syndrome with description of 3 cases diagnosed in this Department.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2616809"}, {"offsetInBeginSection": 132, "offsetInEndSection": 247, "text": "The clinical manifestations of the syndrome contains no pathognomonic symptoms and suggests rather cholecystopathy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2616809"}, {"offsetInBeginSection": 248, "offsetInEndSection": 311, "text": "This is possibly the cause of rare recognition of the syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2616809"}, {"offsetInBeginSection": 0, "offsetInEndSection": 18, "text": "[Zieve's syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/464793"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "The Zieve's syndrome consists of the transient association of cholestatic jaundice, hemolytic anemia, hyperlipemia, in a chronic alcoholic.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/464793"}, {"offsetInBeginSection": 140, "offsetInEndSection": 365, "text": "The Authors, after a short introduction regarding physiopathological problems, describe and subsequently examine on the clinical ground a recent personal observation, which had been mentioned for the rarene-s of this disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/464793"}]}, {"id": "5a7636d39e632bc066000004", "body": "Which R packages have been developed for the discovery of mutational signatures in cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27091472", "http://www.ncbi.nlm.nih.gov/pubmed/29028923", "http://www.ncbi.nlm.nih.gov/pubmed/29145625", "http://www.ncbi.nlm.nih.gov/pubmed/27591080", "http://www.ncbi.nlm.nih.gov/pubmed/26163694"], "snippets": [{"offsetInBeginSection": 485, "offsetInEndSection": 697, "text": "To make such analyses accessible to a wider community of researchers with no programming expertise, we have developed within the web-based user-friendly platform Galaxy a first-of-its-kind package called MutSpec.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27091472"}, {"offsetInBeginSection": 697, "offsetInEndSection": 974, "text": "RESULTS: MutSpec includes a set of tools that perform variant annotation and use advanced statistics for the identification of mutation signatures present in cancer genomes and for comparing the obtained signatures with those published in the COSMIC database and other sources.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27091472"}, {"offsetInBeginSection": 975, "offsetInEndSection": 1155, "text": "MutSpec offers an accessible framework for building reproducible analysis pipelines, integrating existing methods and scripts developed in-house with publicly available R packages.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27091472"}, {"offsetInBeginSection": 1807, "offsetInEndSection": 1953, "text": "MutSpec can thus effectively assist in the discovery of complex mutational processes resulting from exogenous and endogenous carcinogenic insults.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27091472"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Detecting presence of mutational signatures in cancer with confidence.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028923"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Motivation: Cancers arise as the result of somatically acquired changes in the DNA of cancer cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028923"}, {"offsetInBeginSection": 100, "offsetInEndSection": 379, "text": "However, in addition to the mutations that confer a growth advantage, cancer genomes accumulate a large number of somatic mutations resulting from normal DNA damage and repair processes as well as carcinogenic exposures or cancer related aberrations of DNA maintenance machinery.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028923"}, {"offsetInBeginSection": 380, "offsetInEndSection": 484, "text": "These mutagenic processes often produce characteristic mutational patterns called mutational signatures.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028923"}, {"offsetInBeginSection": 729, "offsetInEndSection": 1062, "text": "Hence, one needs to be able to not only decompose a patient's mutational profile into signatures but also establish the accuracy of such decomposition.Results: We proposed two complementary ways of measuring confidence and stability of decomposition results and applied them to analyze mutational signatures in breast cancer genomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028923"}, {"offsetInBeginSection": 1063, "offsetInEndSection": 1208, "text": "We identified both very stable and highly unstable signatures, as well as signatures that previously have not been associated with breast cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028923"}]}, {"id": "5a8dc57ffcd1d6a10c000025", "body": "Are the human bombesin receptors, GRPR and NMBR, frequently overexpressed G-protein-coupled-receptors by lung-cancers?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10828496", "http://www.ncbi.nlm.nih.gov/pubmed/23096238", "http://www.ncbi.nlm.nih.gov/pubmed/12959933", "http://www.ncbi.nlm.nih.gov/pubmed/8018339", "http://www.ncbi.nlm.nih.gov/pubmed/19628633", "http://www.ncbi.nlm.nih.gov/pubmed/11463790", "http://www.ncbi.nlm.nih.gov/pubmed/10679759", "http://www.ncbi.nlm.nih.gov/pubmed/23826298", "http://www.ncbi.nlm.nih.gov/pubmed/25209280", "http://www.ncbi.nlm.nih.gov/pubmed/26030739"], "snippets": [{"offsetInBeginSection": 122, "offsetInEndSection": 304, "text": "The antagonists of bombesin/gastrin-releasing peptide (GRP) suppress the proliferation of diverse tumors including ovarian cancer by mechanisms likely mediated by bombesin receptors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10828496"}, {"offsetInBeginSection": 305, "offsetInEndSection": 668, "text": "In this study, we used the reverse transcription-polymerase chain reaction (RT-PCR) method to evaluate the mRNA expression of three bombesin receptor subtypes: gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype 3 (BRS-3), in 22 specimens of human epithelial ovarian cancer and in two human ovarian cancer lines.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10828496"}, {"offsetInBeginSection": 861, "offsetInEndSection": 1006, "text": "Thus, 14 of 22 specimens ( approximately 64%) expressed mRNAs for both GRPR and NMBR, and five ( approximately 23%) expressed all three subtypes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10828496"}, {"offsetInBeginSection": 1599, "offsetInEndSection": 1731, "text": "Our study indicates that GRPR and NMBR are widely distributed in human ovarian carcinomas with BRS-3 being found in Stage IV tumors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10828496"}, {"offsetInBeginSection": 1732, "offsetInEndSection": 1873, "text": "Some approaches based on bombesin/GRP receptor antagonists or targeted bombesin analogs could be considered for treatment of ovarian cancers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10828496"}, {"offsetInBeginSection": 0, "offsetInEndSection": 49, "text": "Bombesin receptor regulation of emotional memory.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23096238"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "Mammalian bombesin-like peptides neuromedin B (NMB) and gastrin-releasing peptide (GRP) act by activating NMB receptors (NMBR, BBl) and GRP receptors (GRPR,BB2), respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23096238"}, {"offsetInBeginSection": 176, "offsetInEndSection": 443, "text": "These two bombesin receptors are members of the G-protein-coupled receptor (GPCR) superfamily.In the brain, NMBR and GRPR are highly expressed in the brain areas involved in memory processing and emotional responses, such as the hippocampus and the amygdaloid nuclei.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23096238"}, {"offsetInBeginSection": 779, "offsetInEndSection": 948, "text": "GRPR signaling interacts with multiple protein kinase pathways as well as with other neurotransmitter,hormone, and growth factor systems in influencing memory formation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23096238"}, {"offsetInBeginSection": 949, "offsetInEndSection": 1148, "text": "Together with evidence from human studies, the findings from rodent experiments suggest that bombesin receptors may be therapeutic targets in brain disorders involving memory dysfunction and anxiety.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23096238"}]}, {"id": "5a7602be83b0d9ea6600000f", "body": "Describe King\u2013Kopetzky syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16760737", "http://www.ncbi.nlm.nih.gov/pubmed/20512338", "http://www.ncbi.nlm.nih.gov/pubmed/25709171", "http://www.ncbi.nlm.nih.gov/pubmed/835533", "http://www.ncbi.nlm.nih.gov/pubmed/4017281", "http://www.ncbi.nlm.nih.gov/pubmed/9777339", "http://www.ncbi.nlm.nih.gov/pubmed/6703533", "http://www.ncbi.nlm.nih.gov/pubmed/17326116", "http://www.ncbi.nlm.nih.gov/pubmed/23565480", "http://www.ncbi.nlm.nih.gov/pubmed/3144988"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 47, "text": "Two brothers with Goldberg-Shprintzen syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16760737"}, {"offsetInBeginSection": 309, "offsetInEndSection": 505, "text": "The novel findings in this instance are of foot anomalies including camptodactyly and clinodactyly of the 2nd to 4th toes, which have not been previously described in Goldberg-Shprintzen syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16760737"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "Ortner's syndrome as a presenting feature of giant cell arteritis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20512338"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "A rare newly described overgrowth syndrome with vascular malformations-Cloves syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25709171"}, {"offsetInBeginSection": 113, "offsetInEndSection": 213, "text": "We describe a rare, newly described syndrome with features of overgrowth and vascular malformations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25709171"}, {"offsetInBeginSection": 156, "offsetInEndSection": 264, "text": "The syndrome could be a new one, although it has several features resembling those described by Lowry et al.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/835533"}, {"offsetInBeginSection": 265, "offsetInEndSection": 349, "text": "It is suggested that this syndrome is inherited as an autosomal-recessive condition.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/835533"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Multiple dysmorphic features and pancytopenia: a new syndrome?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/4017281"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Various degrees of bone marrow aplasia have been described in association with distinctive congenital anomalies such as the Fanconi Pancytopenia Syndrome (F.P.S.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/4017281"}, {"offsetInBeginSection": 211, "offsetInEndSection": 267, "text": "Syndrome) the Aase Syndrome and Diamond-Blackfan Anemia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/4017281"}]}, {"id": "5a67c284b750ff4455000011", "body": "What is GenomeVIP?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28522612"], "snippets": []}, {"id": "5a981e66fcd1d6a10c00002f", "body": "According to guidelines, insulin resistance is one risk factor in the diagnosis of metabolic syndrome, name 3 more risk factors.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16762931", "http://www.ncbi.nlm.nih.gov/pubmed/15547646", "http://www.ncbi.nlm.nih.gov/pubmed/16505579", "http://www.ncbi.nlm.nih.gov/pubmed/12643148", "http://www.ncbi.nlm.nih.gov/pubmed/15940204", "http://www.ncbi.nlm.nih.gov/pubmed/21068471", "http://www.ncbi.nlm.nih.gov/pubmed/17125447", "http://www.ncbi.nlm.nih.gov/pubmed/17456293", "http://www.ncbi.nlm.nih.gov/pubmed/19108808", "http://www.ncbi.nlm.nih.gov/pubmed/15529616"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Does a diagnosis of metabolic syndrome have value in clinical practice?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762931"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "\"The metabolic syndrome\" is the name for a clustering of risk factors for cardiovascular disease and type 2 diabetes that are of metabolic origin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762931"}, {"offsetInBeginSection": 147, "offsetInEndSection": 304, "text": "These risk factors consist of atherogenic dyslipidemia, elevated blood pressure, elevated plasma glucose, a prothrombotic state, and a proinflammatory state.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762931"}, {"offsetInBeginSection": 305, "offsetInEndSection": 417, "text": "There are 2 major, interacting causes of the metabolic syndrome-obesity and endogenous metabolic susceptibility.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762931"}, {"offsetInBeginSection": 418, "offsetInEndSection": 475, "text": "The latter typically is manifested by insulin resistance.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762931"}, {"offsetInBeginSection": 476, "offsetInEndSection": 626, "text": "The metabolic syndrome is accompanied by a 2-fold increase in the risk of cardiovascular disease and a 5-fold increase in the risk of type 2 diabetes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762931"}, {"offsetInBeginSection": 627, "offsetInEndSection": 751, "text": "A clinical diagnosis of the metabolic syndrome is useful because it affects therapeutic strategy in patients at higher risk.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762931"}, {"offsetInBeginSection": 752, "offsetInEndSection": 856, "text": "However, there are 2 views about the best therapeutic strategy for patients with the metabolic syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762931"}, {"offsetInBeginSection": 857, "offsetInEndSection": 957, "text": "One view holds that each of the metabolic risk factors should be singled out and treated separately.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762931"}, {"offsetInBeginSection": 1100, "offsetInEndSection": 1231, "text": "The latter approach emphasizes lifestyle therapies (weight reduction and increased exercise), which target all of the risk factors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762931"}]}, {"id": "5a76080683b0d9ea66000015", "body": "Is cilengitide effective for treatment of glioblastoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21739168", "http://www.ncbi.nlm.nih.gov/pubmed/25163906", "http://www.ncbi.nlm.nih.gov/pubmed/24014381", "http://www.ncbi.nlm.nih.gov/pubmed/24442484", "http://www.ncbi.nlm.nih.gov/pubmed/23354807", "http://www.ncbi.nlm.nih.gov/pubmed/22866207", "http://www.ncbi.nlm.nih.gov/pubmed/22976135", "http://www.ncbi.nlm.nih.gov/pubmed/21417900", "http://www.ncbi.nlm.nih.gov/pubmed/17277694", "http://www.ncbi.nlm.nih.gov/pubmed/18616418"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21739168"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Cilengitide is a cyclic pentapeptide that is a specific inhibitor of the \u03b1v\u03b23 and \u03b1v\u03b25 integrins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21739168"}, {"offsetInBeginSection": 98, "offsetInEndSection": 210, "text": "Preclinical studies demonstrate antiangiogenic activity and anti-invasive activity in a number of glioma models.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21739168"}, {"offsetInBeginSection": 211, "offsetInEndSection": 334, "text": "This study was designed to evaluate the efficacy and tumor delivery of cilengitide in patients with recurrent glioblastoma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21739168"}, {"offsetInBeginSection": 335, "offsetInEndSection": 618, "text": "Patients with recurrent glioblastoma who require a surgical resection for optimal clinical care received 3 intravenous doses of cilengitide at either 500 or 2000 mg (day -8, -4, -1) prior to undergoing tumor resection with corresponding blood samples for plasma to tumor comparisons.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21739168"}, {"offsetInBeginSection": 749, "offsetInEndSection": 839, "text": "The study accrued 30 patients with recurrent glioblastoma, 26 were evaluable for efficacy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21739168"}, {"offsetInBeginSection": 892, "offsetInEndSection": 1090, "text": "Cilengitide was detected in all tumor specimens with higher levels in the group receiving 2000 mg dosing while corresponding plasma concentrations were low, often below the lower limit of detection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21739168"}, {"offsetInBeginSection": 1160, "offsetInEndSection": 1342, "text": "This study provides evidence that with established dosing, cilengitide is adequately delivered to the tumor, although as a single agent, efficacy in recurrent glioblastoma is modest.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21739168"}, {"offsetInBeginSection": 619, "offsetInEndSection": 700, "text": "After recovery from surgery, patients were treated with cilengitide (2000 mg i.v.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21739168"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25163906"}]}, {"id": "5a6a3464b750ff4455000026", "body": "Which algorithm has been developed in order to improve multiple circular sequence alignment using refined sequences?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28088189", "http://www.ncbi.nlm.nih.gov/pubmed/19627599"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "MARS: improving multiple circular sequence alignment using refined sequences.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "BACKGROUND: A fundamental assumption of all widely-used multiple sequence alignment techniques is that the left- and right-most positions of the input sequences are relevant to the alignment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189"}, {"offsetInBeginSection": 192, "offsetInEndSection": 477, "text": "However, the position where a sequence starts or ends can be totally arbitrary due to a number of reasons: arbitrariness in the linearisation (sequencing) of a circular molecular structure; or inconsistencies introduced into sequence databases due to different linearisation standards.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189"}, {"offsetInBeginSection": 478, "offsetInEndSection": 664, "text": "These scenarios are relevant, for instance, in the process of multiple sequence alignment of mitochondrial DNA, viroid, viral or other genomes, which have a circular molecular structure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189"}, {"offsetInBeginSection": 665, "offsetInEndSection": 915, "text": "A solution for these inconsistencies would be to identify a suitable rotation (cyclic shift) for each sequence; these refined sequences may in turn lead to improved multiple sequence alignments using the preferred multiple sequence alignment program.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189"}, {"offsetInBeginSection": 915, "offsetInEndSection": 1039, "text": "RESULTS: We present MARS, a new heuristic method for improving Multiple circular sequence Alignment using Refined Sequences.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189"}, {"offsetInBeginSection": 1196, "offsetInEndSection": 1468, "text": "Experimental results, using real and synthetic data, show that MARS improves the alignments, with respect to standard genetic measures and the inferred maximum-likelihood-based phylogenies, and outperforms state-of-the-art methods both in terms of accuracy and efficiency.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189"}, {"offsetInBeginSection": 1469, "offsetInEndSection": 1725, "text": "Our results show, among others, that the average pairwise distance in the multiple sequence alignment of a dataset of widely-studied mitochondrial DNA sequences is reduced by around 5% when MARS is applied before a multiple sequence alignment is performed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189"}, {"offsetInBeginSection": 2020, "offsetInEndSection": 2177, "text": "We present here a method, which can be used in conjunction with any multiple sequence alignment program, to address this problem effectively and efficiently.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "CSA: an efficient algorithm to improve circular DNA multiple alignment.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19627599"}]}, {"id": "5a74e9ad0384be955100000a", "body": "What is a SERM?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11795362", "http://www.ncbi.nlm.nih.gov/pubmed/24667357", "http://www.ncbi.nlm.nih.gov/pubmed/26343247", "http://www.ncbi.nlm.nih.gov/pubmed/12036407", "http://www.ncbi.nlm.nih.gov/pubmed/24930824", "http://www.ncbi.nlm.nih.gov/pubmed/20446043", "http://www.ncbi.nlm.nih.gov/pubmed/23925896", "http://www.ncbi.nlm.nih.gov/pubmed/18279543", "http://www.ncbi.nlm.nih.gov/pubmed/28978566", "http://www.ncbi.nlm.nih.gov/pubmed/15500393"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 46, "text": "What would be the properties of an ideal SERM?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11795362"}, {"offsetInBeginSection": 0, "offsetInEndSection": 221, "text": "Selective estrogen receptor modulators (SERMs) are drugs that bind to the estrogen receptor (ER); in some tissues they act like estrogen (agonists), while in other tissues they oppose the action of estrogen (antagonists).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11795362"}, {"offsetInBeginSection": 222, "offsetInEndSection": 414, "text": "The SERM tamoxifen acts as an estrogen antagonist in the breast in that it prevents and treats breast cancer, but it acts as an estrogen agonist in the endometrium, where it can induce cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11795362"}, {"offsetInBeginSection": 415, "offsetInEndSection": 509, "text": "Estrogen, and to a lesser extent SERMs, are effective in preventing and treating osteoporosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11795362"}, {"offsetInBeginSection": 510, "offsetInEndSection": 787, "text": "Contrary to the prevalent hypothesis that estrogen provides benefit to women with regard to secondary prevention of coronary heart disease (CHD), randomized clinical trials have demonstrated that estrogen is associated with an increased risk of CHD in this population of women.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11795362"}, {"offsetInBeginSection": 1284, "offsetInEndSection": 1484, "text": "Data on the beneficial and adverse effects of estrogen and SERMs are reported along with an elaboration of the constellation of properties that would characterize an ideal SERM working through the ER.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11795362"}, {"offsetInBeginSection": 0, "offsetInEndSection": 259, "text": "Selective estrogen receptor modulators (SERMs) are compounds that exhibit tissue-specific estrogen receptor (ER) agonist or antagonist activity, and are used for various indications, including treatment of breast cancer, osteoporosis, and menopausal symptoms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24667357"}, {"offsetInBeginSection": 805, "offsetInEndSection": 1064, "text": "Continuing advances in the understanding of SERM mechanisms of action and structural interactions with the ER may lead to the development of new agents and combinations of agents to provide optimal treatments to meet the varying needs of postmenopausal women.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24667357"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Effect of a selective estrogen receptor modulator on bone formation in osteoporotic spine fusion using an ovariectomized rat model.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26343247"}, {"offsetInBeginSection": 11, "offsetInEndSection": 104, "text": "CONTEXT: Selective estrogen receptor modulators (SERMs) are drugs used to treat osteoporosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26343247"}]}, {"id": "5a7610ca83b0d9ea6600001b", "body": "What is the role of nimotuzumab in treatment of pontine glioma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24696052", "http://www.ncbi.nlm.nih.gov/pubmed/25926743", "http://www.ncbi.nlm.nih.gov/pubmed/24847085", "http://www.ncbi.nlm.nih.gov/pubmed/23754473", "http://www.ncbi.nlm.nih.gov/pubmed/21171927", "http://www.ncbi.nlm.nih.gov/pubmed/23926436", "http://www.ncbi.nlm.nih.gov/pubmed/23043252"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696052"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Radiotherapy is the only treatment definitely indicated for diffuse pontine gliomas (DIPG).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696052"}, {"offsetInBeginSection": 92, "offsetInEndSection": 228, "text": "Findings on the role of EGFR signaling in the onset of childhood DIPG prompted the use of nimotuzumab, an anti-EGFR monoclonal antibody.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696052"}, {"offsetInBeginSection": 646, "offsetInEndSection": 831, "text": "Vinorelbine 20 mg/m(2) was administered weekly, with nimotuzumab 150 mg/m(2) in the first 12 weeks of treatment; radiotherapy was delivered from weeks 3 to 9, for a total dose of 54 Gy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696052"}, {"offsetInBeginSection": 1256, "offsetInEndSection": 1348, "text": "The nimotuzumab/vinorelbine combination was very well tolerated, with no acute side-effects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696052"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "Profile of nimotuzumab in the treatment of high-grade glioma.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25926743"}, {"offsetInBeginSection": 304, "offsetInEndSection": 498, "text": "We review the humanized epidermal growth factor receptor (EGFR) and the major EGFR target drugs in HGG treatments, focusing on the EGFR antibody nimotuzumab as a new therapeutic strategy in HGG.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25926743"}, {"offsetInBeginSection": 499, "offsetInEndSection": 772, "text": "We found that nimotuzumab with or without radiotherapy, chemotherapy in newly diagnosed or recurrent HGG, such as glioblastoma multiforme (GBM), anaplastic astrocytomas (AA), and diffuse intrinsic pontine glioma (DIPG), might improve the response rate or the survival time.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25926743"}, {"offsetInBeginSection": 773, "offsetInEndSection": 917, "text": "In conclusion, nimotuzumab is a very well-tolerated drug with acceptable toxicity, and it may have promising value in the combination treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25926743"}, {"offsetInBeginSection": 918, "offsetInEndSection": 1076, "text": "As a result, multiple center randomized controlled Phase III clinical trials need to be conducted to confirm the efficacy and toxicity for nimotuzumab in HGG.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25926743"}]}, {"id": "5a6a35b7b750ff4455000027", "body": "What is libgapmis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24564250"], "snippets": []}, {"id": "5a76016683b0d9ea6600000d", "body": "Down's syndrome occurs when an individual has an extra copy or part of a copy of chromosome 21, yes or no?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19458618", "http://www.ncbi.nlm.nih.gov/pubmed/25738006", "http://www.ncbi.nlm.nih.gov/pubmed/1838097", "http://www.ncbi.nlm.nih.gov/pubmed/19212162", "http://www.ncbi.nlm.nih.gov/pubmed/11399108", "http://www.ncbi.nlm.nih.gov/pubmed/28959732", "http://www.ncbi.nlm.nih.gov/pubmed/26243569", "http://www.ncbi.nlm.nih.gov/pubmed/2880544"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458618"}, {"offsetInBeginSection": 0, "offsetInEndSection": 271, "text": "The incidence of many cancer types is significantly reduced in individuals with Down's syndrome, and it is thought that this broad cancer protection is conferred by the increased expression of one or more of the 231 supernumerary genes on the extra copy of chromosome 21.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458618"}, {"offsetInBeginSection": 272, "offsetInEndSection": 494, "text": "One such gene is Down's syndrome candidate region-1 (DSCR1, also known as RCAN1), which encodes a protein that suppresses vascular endothelial growth factor (VEGF)-mediated angiogenic signalling by the calcineurin pathway.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458618"}, {"offsetInBeginSection": 495, "offsetInEndSection": 599, "text": "Here we show that DSCR1 is increased in Down's syndrome tissues and in a mouse model of Down's syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458618"}, {"offsetInBeginSection": 917, "offsetInEndSection": 1094, "text": "We also provide evidence that attenuation of calcineurin activity by DSCR1, together with another chromosome 21 gene Dyrk1a, may be sufficient to markedly diminish angiogenesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458618"}, {"offsetInBeginSection": 1095, "offsetInEndSection": 1335, "text": "These data provide a mechanism for the reduced cancer incidence in Down's syndrome and identify the calcineurin signalling pathway, and its regulators DSCR1 and DYRK1A, as potential therapeutic targets in cancers arising in all individuals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458618"}, {"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "Downs syndrome (DS) occurs due to an extra copy of chromosome 21.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25738006"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Chromosomal distribution of cloned human alpha-satellite DNA alpha R1-6 has been studied by in situ hybridization technique.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1838097"}, {"offsetInBeginSection": 125, "offsetInEndSection": 245, "text": "The sequence under study has been shown to be predominantly located in the centromeric regions of chromosomes 13 and 21.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1838097"}, {"offsetInBeginSection": 246, "offsetInEndSection": 439, "text": "Intercellular variability of labelling patterns in every person under analysis being insignificant, there exists strong individual variability of interchromosomal distribution of the satellite.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1838097"}]}, {"id": "5a7615af83b0d9ea6600001f", "body": "Is vorinostat effective for glioblastoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20135194", "http://www.ncbi.nlm.nih.gov/pubmed/24576944", "http://www.ncbi.nlm.nih.gov/pubmed/29016887", "http://www.ncbi.nlm.nih.gov/pubmed/19307505", "http://www.ncbi.nlm.nih.gov/pubmed/23996800", "http://www.ncbi.nlm.nih.gov/pubmed/22028388", "http://www.ncbi.nlm.nih.gov/pubmed/22086447", "http://www.ncbi.nlm.nih.gov/pubmed/24838514", "http://www.ncbi.nlm.nih.gov/pubmed/22090453", "http://www.ncbi.nlm.nih.gov/pubmed/22923449"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20135194"}, {"offsetInBeginSection": 0, "offsetInEndSection": 196, "text": "Histone deacetylase (HDAC) inhibitors represent a promising class of anti-cancer agents that are actively being evaluated in the context of clinical trials in solid tumors, including glioblastoma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20135194"}, {"offsetInBeginSection": 386, "offsetInEndSection": 693, "text": "As recent investigations suggest HDAC inhibitors may potentiate the cytotoxicity of topoisomerase inhibitors, which continue to be a commonly used class of agents in the treatment of glioblastoma, we performed preclinical studies to determine if this combination may be a promising strategy in glioblastoma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20135194"}, {"offsetInBeginSection": 694, "offsetInEndSection": 862, "text": "The effects of the HDAC inhibitor vorinostat and SN38, which is the active metabolite of the topoisomerase I inhibitor CPT-11, was evaluated using the clonogenic assay.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20135194"}, {"offsetInBeginSection": 1183, "offsetInEndSection": 1255, "text": "Vorinostat enhanced the cytotoxicity of SN38 in glioblastoma cell lines.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20135194"}, {"offsetInBeginSection": 1399, "offsetInEndSection": 1483, "text": "Vorinostat potentiated SN38-induced DNA DSBs and attenuated their subsequent repair.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20135194"}, {"offsetInBeginSection": 1484, "offsetInEndSection": 1680, "text": "These results indicate vorinostat enhances the cytotoxicity of SN38 in glioblastoma cell lines, suggesting this combination may be a worthwhile strategy to test in the context of a clinical trial.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20135194"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Hemolytic anemia in two patients with glioblastoma multiforme: A possible interaction between vorinostat and dapsone.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24576944"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "Patients undergoing treatment for glioblastoma multiforme are routinely placed on prophylactic treatment for Pneumocystis jirovecii pneumonia because of significant therapy-induced lymphopenia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24576944"}, {"offsetInBeginSection": 709, "offsetInEndSection": 826, "text": "A single case report of dapsone-induced hemolytic anemia in a patient with glioblastoma multiforme has been reported.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24576944"}]}, {"id": "5a6a7869b750ff4455000028", "body": "Describe SNP2TFBS", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27899579"], "snippets": []}, {"id": "5a7706b79e632bc066000009", "body": "What is trismus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26098612", "http://www.ncbi.nlm.nih.gov/pubmed/26058916", "http://www.ncbi.nlm.nih.gov/pubmed/23193958", "http://www.ncbi.nlm.nih.gov/pubmed/20236743", "http://www.ncbi.nlm.nih.gov/pubmed/24985733", "http://www.ncbi.nlm.nih.gov/pubmed/24669774", "http://www.ncbi.nlm.nih.gov/pubmed/22632890", "http://www.ncbi.nlm.nih.gov/pubmed/28122104", "http://www.ncbi.nlm.nih.gov/pubmed/27461633", "http://www.ncbi.nlm.nih.gov/pubmed/27627138"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Trismus in patients with head and neck cancer: etiopathogenesis, diagnosis and management.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26098612"}, {"offsetInBeginSection": 82, "offsetInEndSection": 145, "text": "A mouth opening of 35 mm or less should be regarded as trismus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26098612"}, {"offsetInBeginSection": 561, "offsetInEndSection": 671, "text": "Trismus may worsen or remain the same over time, or the symptoms may reduce, even in the absence of treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26098612"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Trismus is characterized by a reduced ability to open the mouth, directly affecting many aspects of daily life, such as chewing, swallowing, speaking and maintaining oral hygiene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26058916"}, {"offsetInBeginSection": 454, "offsetInEndSection": 600, "text": "Several stretching techniques and jaw mobilizing devices are available, but their effect in radiotherapy-induced trismus is still largely unknown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26058916"}, {"offsetInBeginSection": 96, "offsetInEndSection": 238, "text": "To date there are few prospective studies regarding the incidence of trismus and the patients' experience of trismus in daily life activities.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23193958"}, {"offsetInBeginSection": 1240, "offsetInEndSection": 1343, "text": "Trismus severely impairs HRQL and negatively affects daily life activities in patients with H&N cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23193958"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Trismus is a serious problem for some patients after oral and oropharyngeal cancer, and it has a detrimental impact on quality of life and function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20236743"}, {"offsetInBeginSection": 841, "offsetInEndSection": 1021, "text": "Using a criterion of 35 mm or less as an indication of trismus, 30% (19/63) had trismus before operation, 65% (37/57) at hospital discharge, and 54% (26/48) at six month follow-up.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20236743"}, {"offsetInBeginSection": 1219, "offsetInEndSection": 1282, "text": "Trismus at discharge was a prediction of trismus at six months.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20236743"}]}, {"id": "5a67ab79b750ff445500000b", "body": "CURB65 score is used for stratification of which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28168816", "http://www.ncbi.nlm.nih.gov/pubmed/20529344", "http://www.ncbi.nlm.nih.gov/pubmed/20920140", "http://www.ncbi.nlm.nih.gov/pubmed/18304365", "http://www.ncbi.nlm.nih.gov/pubmed/16928720", "http://www.ncbi.nlm.nih.gov/pubmed/21539743", "http://www.ncbi.nlm.nih.gov/pubmed/24931899"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Lactate levels and pneumonia severity index are good predictors of in-hospital mortality in pneumonia.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28168816"}, {"offsetInBeginSection": 280, "offsetInEndSection": 387, "text": "METHODS: This prospective cross-sectional study performed in a third level education and research hospital.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28168816"}, {"offsetInBeginSection": 925, "offsetInEndSection": 1087, "text": "DISCUSSION: The early prediction of the mortality risk is important to determine the high risk patients to hospitalize in intensive care unit and close follow up.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28168816"}, {"offsetInBeginSection": 1088, "offsetInEndSection": 1170, "text": "The lactate level, PSI score and CURB_65 scores are good predictors for mortality.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28168816"}, {"offsetInBeginSection": 1171, "offsetInEndSection": 1236, "text": "We can use them in emergency departments for risk stratification.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28168816"}, {"offsetInBeginSection": 0, "offsetInEndSection": 230, "text": "INTRODUCTION: Measurement of prohormones representing different pathophysiological pathways could enhance risk stratification in patients with community-acquired pneumonia (CAP) and other lower respiratory tract infections (LRTI).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20529344"}, {"offsetInBeginSection": 857, "offsetInEndSection": 967, "text": "RESULTS: During the 30 days of follow-up, 134 serious complications occurred in 925 (14.5%) patients with CAP.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20529344"}, {"offsetInBeginSection": 1072, "offsetInEndSection": 1226, "text": "ProADM or proET1 alone had stronger discriminatory powers than the PSI or CURB65 score or any of either score components to predict serious complications.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20529344"}, {"offsetInBeginSection": 1428, "offsetInEndSection": 1620, "text": "CONCLUSIONS: Five biomarkers from distinct biologic pathways were strong and specific predictors for short-term adverse outcome and improved clinical risk scores in CAP and non-pneumonic LRTI.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20529344"}, {"offsetInBeginSection": 517, "offsetInEndSection": 857, "text": "We compared the prognostic accuracy of these biomarkers with the pneumonia severity index (PSI) and CURB65 (Confusion, Urea, Respiratory rate, Blood pressure, Age 65) score to predict serious complications defined as death, ICU admission and disease-specific complications using receiver operating curves (ROC) and reclassification methods.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20529344"}]}, {"id": "5a6cfe27b750ff4455000029", "body": "What is SMiLE-seq?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28092692"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "SMiLE-seq identifies binding motifs of single and dimeric transcription factors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692"}, {"offsetInBeginSection": 127, "offsetInEndSection": 303, "text": "Here, we present a novel, semiautomated protein-DNA interaction characterization technology, selective microfluidics-based ligand enrichment followed by sequencing (SMiLE-seq).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692"}, {"offsetInBeginSection": 304, "offsetInEndSection": 503, "text": "SMiLE-seq is neither limited by DNA bait length nor biased toward strong affinity binders; it probes the DNA-binding properties of TFs over a wide affinity range in a fast and cost-effective fashion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692"}, {"offsetInBeginSection": 504, "offsetInEndSection": 621, "text": "We validated SMiLE-seq by analyzing 58 full-length human, mouse, and Drosophila TFs from distinct structural classes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692"}]}, {"id": "5a77072c9e632bc06600000a", "body": "What is craniosynostosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29093661", "http://www.ncbi.nlm.nih.gov/pubmed/17980312", "http://www.ncbi.nlm.nih.gov/pubmed/27622416", "http://www.ncbi.nlm.nih.gov/pubmed/27226847", "http://www.ncbi.nlm.nih.gov/pubmed/26910679", "http://www.ncbi.nlm.nih.gov/pubmed/24071792", "http://www.ncbi.nlm.nih.gov/pubmed/20108486", "http://www.ncbi.nlm.nih.gov/pubmed/28623672", "http://www.ncbi.nlm.nih.gov/pubmed/28654618", "http://www.ncbi.nlm.nih.gov/pubmed/18344207"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Craniosynostosis is a heterogeneous condition caused by the premature fusion of cranial sutures, occurring mostly as an isolated anomaly.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29093661"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Craniosynostosis is a defect of the skull caused by early fusion of one or more of the cranial sutures and affects 3 to 5 individuals per 10,000 live births.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17980312"}, {"offsetInBeginSection": 158, "offsetInEndSection": 239, "text": "Craniosynostosis can be divided into two main groups: syndromic and nonsyndromic.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17980312"}, {"offsetInBeginSection": 543, "offsetInEndSection": 603, "text": "More than 180 syndromes exist that contain craniosynostosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17980312"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Craniosynostosis: prenatal diagnosis by 2D/3D ultrasound, magnetic resonance imaging and computed tomography.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27622416"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Craniosynostosis is defined as the process of premature fusion of one or more of the cranial sutures.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27622416"}, {"offsetInBeginSection": 172, "offsetInEndSection": 231, "text": "Craniosynostosis may be classified in primary or secondary.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27622416"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Craniosynostosis is defined as the premature fusion of one or more of the cranial sutures.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27226847"}, {"offsetInBeginSection": 239, "offsetInEndSection": 331, "text": "Craniosynostosis is very heterogeneous in terms of its causes, presentation, and management.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27226847"}, {"offsetInBeginSection": 1249, "offsetInEndSection": 1397, "text": "Compared to the other types of craniosynostosis, single gene mutations can be more frequently detected, in one-third of coronal synostosis patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27226847"}]}, {"id": "5a67b152b750ff445500000e", "body": "Describe nursemaid's elbow injury.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19657259", "http://www.ncbi.nlm.nih.gov/pubmed/27294496", "http://www.ncbi.nlm.nih.gov/pubmed/21317693", "http://www.ncbi.nlm.nih.gov/pubmed/11153321", "http://www.ncbi.nlm.nih.gov/pubmed/7773660", "http://www.ncbi.nlm.nih.gov/pubmed/7560033"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 50, "text": "Nursemaid's elbow: a preventable pediatric injury.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19657259"}, {"offsetInBeginSection": 144, "offsetInEndSection": 227, "text": "Nursemaid's elbow is a common injury in young children that can often be prevented.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19657259"}, {"offsetInBeginSection": 228, "offsetInEndSection": 323, "text": "This injury occurs when the radial head subluxates from its normal position at the elbow joint.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19657259"}, {"offsetInBeginSection": 324, "offsetInEndSection": 444, "text": "Activities such as swinging a child by the hands or pulling on the pronated upper extremity can cause nursemaid's elbow.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19657259"}, {"offsetInBeginSection": 445, "offsetInEndSection": 605, "text": "Prevention of nursemaid's elbow in children may be accomplished with education of parents, daycare workers, and teachers on the mechanism of this common injury.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19657259"}, {"offsetInBeginSection": 0, "offsetInEndSection": 55, "text": "Elbow Pain After a Fall: Nursemaid's Elbow or Fracture?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27294496"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Nursemaid's elbow and elbow fractures are both common causes of acute elbow pain, but the mechanism of injury is quite different.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27294496"}, {"offsetInBeginSection": 295, "offsetInEndSection": 375, "text": "A common clinical mistake is to treat all elbow injuries as a nursemaid's elbow.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27294496"}, {"offsetInBeginSection": 472, "offsetInEndSection": 661, "text": "Occult fractures, also known as \"hairline\" elbow fractures, may not be visible on initial X-rays, but clues to the diagnosis, especially the posterior fat pad, can be helpful in evaluation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27294496"}, {"offsetInBeginSection": 662, "offsetInEndSection": 802, "text": "When an occult fracture is suspected based on history and radiographic findings, the patient's elbow should be immobilized, not manipulated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27294496"}]}, {"id": "5a6d08d5b750ff445500002c", "body": "Which stapled peptide has been designed to target Ctf4?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28815832"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "Targeting the Genome-Stability Hub Ctf4 by Stapled-Peptide Design.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832"}, {"offsetInBeginSection": 491, "offsetInEndSection": 635, "text": "By screening stapling positions in the Sld5 CIP, we identified an unorthodox i,i+6 stapled peptide with improved, submicromolar binding to Ctf4.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832"}, {"offsetInBeginSection": 636, "offsetInEndSection": 749, "text": "The mode of interaction with Ctf4 was confirmed by a crystal structure of the stapled Sld5 peptide bound to Ctf4.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832"}, {"offsetInBeginSection": 750, "offsetInEndSection": 867, "text": "The stapled Sld5 peptide was able to displace the Ctf4 partner DNA polymerase\u2005\u03b1 from the replisome in yeast extracts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832"}]}, {"id": "5a773c50faa1ab7d2e000002", "body": "Has ATF4 transcription factor been linked to cancer and neoplastic transformation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22102693", "http://www.ncbi.nlm.nih.gov/pubmed/21338441"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Stress-regulated transcription factor ATF4 promotes neoplastic transformation by suppressing expression of the INK4a/ARF cell senescence factors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693"}, {"offsetInBeginSection": 0, "offsetInEndSection": 260, "text": "Many cancers overexpress ATF4, a stress-induced transcription factor that promotes cell survival under hypoxic conditions and other stresses of the tumor microenvironment, but the potential contributions of ATF4 to oncogenesis itself have been little explored.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693"}, {"offsetInBeginSection": 261, "offsetInEndSection": 409, "text": "Here, we report that ATF4 promotes oncogene-induced neoplastic transformation by suppressing the expression of cellular senescence-associated genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693"}, {"offsetInBeginSection": 772, "offsetInEndSection": 888, "text": "Elevated levels of ATF4 were sufficient to suppress expression of these proteins and drive oncogenic transformation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Tribbles in disease: Signaling pathways important for cellular function and neoplastic transformation.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21338441"}, {"offsetInBeginSection": 234, "offsetInEndSection": 414, "text": "These include mitogen-activated protein kinase kinase (MAPKK), CCAAT/enhancer-binding protein (C/EBP), activating transcription factor 4 (ATF4) and C/EBP-homologous protein (CHOP).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21338441"}, {"offsetInBeginSection": 518, "offsetInEndSection": 640, "text": "Tribbles proteins are also involved in a series of non-neoplastic disorders including metabolic and neurological diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21338441"}, {"offsetInBeginSection": 641, "offsetInEndSection": 942, "text": "The RAS/mitogen-activated protein kinase (MAPK) pathway molecules (in particular MAPK/ERK kinase 1 (MEK1) and C/EBP transcription factors) include tribbles-binding proteins that are involved in leukemogenesis, and the role of Trib1 as a linker between MAPK signaling and C/EBP degradation is proposed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21338441"}]}, {"id": "5a68eabab750ff4455000015", "body": "Is there an association between Klinefelter syndrome and breast cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22274665", "http://www.ncbi.nlm.nih.gov/pubmed/16106025", "http://www.ncbi.nlm.nih.gov/pubmed/1690312", "http://www.ncbi.nlm.nih.gov/pubmed/7841064", "http://www.ncbi.nlm.nih.gov/pubmed/9283592", "http://www.ncbi.nlm.nih.gov/pubmed/21246928", "http://www.ncbi.nlm.nih.gov/pubmed/3111653", "http://www.ncbi.nlm.nih.gov/pubmed/11976824", "http://www.ncbi.nlm.nih.gov/pubmed/23464700", "http://www.ncbi.nlm.nih.gov/pubmed/20698148"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "Klinefelter syndrome associated with goniodysgenesis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22274665"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "OBJECTIVE: We report a case of a patient with Klinefelter syndrome and glaucoma.CASE", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22274665"}, {"offsetInBeginSection": 197, "offsetInEndSection": 334, "text": "Besides reduced fertility, no characteristic physical or behavioral symptoms for Klinefelter syndrome were found on clinical examination.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22274665"}, {"offsetInBeginSection": 631, "offsetInEndSection": 756, "text": "DISCUSSION: Klinefelter syndrome is the most common cause of male hypogonadism with a variety of clinical signs and symptoms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22274665"}, {"offsetInBeginSection": 874, "offsetInEndSection": 999, "text": "Several other classical features of the syndrome including mental retardation, gynecomastia, and breast cancer are described.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22274665"}, {"offsetInBeginSection": 1000, "offsetInEndSection": 1088, "text": "However, the association between Klinefelter syndrome and ocular manifestations is rare.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22274665"}, {"offsetInBeginSection": 1088, "offsetInEndSection": 1213, "text": "CONCLUSIONS: : Glaucoma or in fact any other ocular manifestations associated with Klinefelter syndrome are rarely described.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22274665"}, {"offsetInBeginSection": 1214, "offsetInEndSection": 1349, "text": "Here, we report a case of glaucoma and its treatment combining trabeculotomy and trabeculectomy in a patient with Klinefelter syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22274665"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16106025"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "BACKGROUND: Men with Klinefelter syndrome have one or more extra X chromosomes and have endocrine abnormalities.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16106025"}]}, {"id": "5a6d1733b750ff4455000030", "body": "Which resource contains accurate enhancer predictions in the developing limb?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28827824"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Limb-Enhancer Genie: An accessible resource of accurate enhancer predictions in the developing limb.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824"}, {"offsetInBeginSection": 142, "offsetInEndSection": 236, "text": "However, reliance on single chromatin marks leads to high rates of false-positive predictions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824"}, {"offsetInBeginSection": 237, "offsetInEndSection": 414, "text": "More sophisticated, integrative methods have been described, but commonly suffer from limited accessibility to the resulting predictions and reduced biological interpretability.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824"}, {"offsetInBeginSection": 415, "offsetInEndSection": 607, "text": "Here we present the Limb-Enhancer Genie (LEG), a collection of highly accurate, genome-wide predictions of enhancers in the developing limb, available through a user-friendly online interface.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824"}, {"offsetInBeginSection": 608, "offsetInEndSection": 854, "text": "We predict limb enhancers using a combination of >50 published limb-specific datasets and clusters of evolutionarily conserved transcription factor binding sites, taking advantage of the patterns observed at previously in vivo validated elements.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824"}, {"offsetInBeginSection": 1285, "offsetInEndSection": 1589, "text": "Moreover, we describe general features that can guide the type of datasets to include when predicting tissue-specific enhancers genome-wide, while providing an accessible resource to the general biological community and facilitating the functional interpretation of genetic studies of limb malformations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824"}]}, {"id": "5a7877c0faa1ab7d2e00000c", "body": "What is the first line treatment for sarcoidosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26357609", "http://www.ncbi.nlm.nih.gov/pubmed/28696638", "http://www.ncbi.nlm.nih.gov/pubmed/26478443", "http://www.ncbi.nlm.nih.gov/pubmed/26419478", "http://www.ncbi.nlm.nih.gov/pubmed/26120005", "http://www.ncbi.nlm.nih.gov/pubmed/26330764", "http://www.ncbi.nlm.nih.gov/pubmed/23196575", "http://www.ncbi.nlm.nih.gov/pubmed/27598883", "http://www.ncbi.nlm.nih.gov/pubmed/27846819", "http://www.ncbi.nlm.nih.gov/pubmed/10719453"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 20, "text": "Hepatic Sarcoidosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26357609"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Sarcoidosis is a multisystem disease characterized by the presence of non-caseating granulomas in affected organs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26357609"}, {"offsetInBeginSection": 115, "offsetInEndSection": 181, "text": "Pulmonary involvement is the most common site of disease activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26357609"}, {"offsetInBeginSection": 182, "offsetInEndSection": 277, "text": "However, hepatic involvement is also common in sarcoidosis, occurring in up to 70% of patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26357609"}, {"offsetInBeginSection": 571, "offsetInEndSection": 667, "text": "Portal hypertension and cirrhosis are complications linked to long-standing hepatic sarcoidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26357609"}, {"offsetInBeginSection": 727, "offsetInEndSection": 835, "text": "It is important to differentiate hepatic sarcoidosis from other autoimmune and granulomatous liver diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26357609"}, {"offsetInBeginSection": 836, "offsetInEndSection": 891, "text": "Not all cases of hepatic sarcoidosis require treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26357609"}, {"offsetInBeginSection": 892, "offsetInEndSection": 992, "text": "For symptomatic patients, the first line treatment includes corticosteroids or ursodeoxycholic acid.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26357609"}, {"offsetInBeginSection": 0, "offsetInEndSection": 41, "text": "[Update on the treatment of sarcoidosis].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28696638"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Sarcoidosis is a granulomatous disease characterized by variable manifestations and course.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28696638"}]}, {"id": "5a68f005b750ff4455000016", "body": "Which personality disorder is treated using dialectical behavior therapy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16173357", "http://www.ncbi.nlm.nih.gov/pubmed/17496179", "http://www.ncbi.nlm.nih.gov/pubmed/9603574", "http://www.ncbi.nlm.nih.gov/pubmed/7977884", "http://www.ncbi.nlm.nih.gov/pubmed/15930077", "http://www.ncbi.nlm.nih.gov/pubmed/19755574", "http://www.ncbi.nlm.nih.gov/pubmed/20579633", "http://www.ncbi.nlm.nih.gov/pubmed/27642799", "http://www.ncbi.nlm.nih.gov/pubmed/18186120", "http://www.ncbi.nlm.nih.gov/pubmed/25373068"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "A proposed trial of dialectical behavior therapy and trauma model therapy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16173357"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Dissociative identity disorder and borderline personality disorder resemble each other in trauma histories and comorbidity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16173357"}, {"offsetInBeginSection": 177, "offsetInEndSection": 340, "text": "Treatment outcome data for Dialectical Behavior Therapy of borderline personality disorder and Trauma Model Therapy of dissociative identity disorder are reviewed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16173357"}, {"offsetInBeginSection": 463, "offsetInEndSection": 671, "text": "The subject groups are borderline personality disorder without dissociative identity disorder; dissociative identity disorder without borderline personality disorder; and both conditions present concurrently.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16173357"}, {"offsetInBeginSection": 672, "offsetInEndSection": 765, "text": "Subjects would be randomized to receive Dialectical Behavior Therapy or Trauma Model Therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16173357"}, {"offsetInBeginSection": 766, "offsetInEndSection": 994, "text": "Such a study could provide answers to controversies in the field about a better treatment approach for dissociative identity disorder and potentially could broaden and strengthen the indications for Dialectical Behavior Therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16173357"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Use of dialectical behavior therapy in borderline personality disorder: a view from residency.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17496179"}, {"offsetInBeginSection": 0, "offsetInEndSection": 241, "text": "OBJECTIVE: The authors describe the use of dialectical behavior therapy (DBT) in treating borderline personality disorder during psychiatry residency, and assess the status of DBT education within psychiatry residencies in the United States.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17496179"}, {"offsetInBeginSection": 241, "offsetInEndSection": 405, "text": "METHOD: The authors present a patient with borderline personality disorder treated by a resident using DBT, along with perspectives from the resident's supervisors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17496179"}, {"offsetInBeginSection": 738, "offsetInEndSection": 843, "text": "The patient in therapy had a tumultuous course, ultimately resulting in the discontinuation of treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17496179"}]}, {"id": "5a6d186db750ff4455000031", "body": "Is there any role of Dlx1 and Dlx2 transcription factors in cortical interneurons?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29028947", "http://www.ncbi.nlm.nih.gov/pubmed/17259176", "http://www.ncbi.nlm.nih.gov/pubmed/17582322", "http://www.ncbi.nlm.nih.gov/pubmed/28821666", "http://www.ncbi.nlm.nih.gov/pubmed/16766712", "http://www.ncbi.nlm.nih.gov/pubmed/19026749"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "The postnatal functions of the Dlx1&2 transcription factors in cortical interneurons (CINs) are unknown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028947"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Dlx homeobox genes play an important role in vertebrate forebrain development.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17259176"}, {"offsetInBeginSection": 855, "offsetInEndSection": 966, "text": "Of importance, there is up-regulated and aberrant expression of NRP-2 in the forebrains of Dlx1/Dlx2 null mice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17259176"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "The tangential migration of GABAergic interneurons to the cortex requires the activity of several transcription factors, but the mechanisms involved have remained elusive.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17582322"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Cellular patterns of transcription factor expression in developing cortical interneurons.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16766712"}, {"offsetInBeginSection": 747, "offsetInEndSection": 928, "text": "This study is a first step to define the combinatorial codes of transcription factors that participate in regulating the specification and function of cortical interneuron subtypes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16766712"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Generation of Cre-transgenic mice using Dlx1/Dlx2 enhancers and their characterization in GABAergic interneurons.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026749"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "DLX1 and DLX2 transcription factors are necessary for forebrain GABAergic neuron differentiation, migration, and survival.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026749"}, {"offsetInBeginSection": 0, "offsetInEndSection": 260, "text": "Most gamma-aminobutyric acidergic interneurons in the neocortex and hippocampus are derived from subpallial progenitors in the medial ganglionic eminence and migrate tangentially to the pallium, where they differentiate into a diverse set of neuronal subtypes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16766712"}]}, {"id": "5a79d0b8faa1ab7d2e00000d", "body": "What cellular process are okazaki fragments associated with?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21278448", "http://www.ncbi.nlm.nih.gov/pubmed/14693726", "http://www.ncbi.nlm.nih.gov/pubmed/28159842", "http://www.ncbi.nlm.nih.gov/pubmed/23451868", "http://www.ncbi.nlm.nih.gov/pubmed/25814667", "http://www.ncbi.nlm.nih.gov/pubmed/19779567", "http://www.ncbi.nlm.nih.gov/pubmed/24035200", "http://www.ncbi.nlm.nih.gov/pubmed/227871", "http://www.ncbi.nlm.nih.gov/pubmed/16427006", "http://www.ncbi.nlm.nih.gov/pubmed/21441898"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 57, "text": "Okazaki fragment maturation: nucleases take centre stage.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "Completion of lagging strand DNA synthesis requires processing of up to 50 million Okazaki fragments per cell cycle in mammalian cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448"}, {"offsetInBeginSection": 136, "offsetInEndSection": 262, "text": "Even in yeast, the Okazaki fragment maturation happens approximately a million times during a single round of DNA replication.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448"}, {"offsetInBeginSection": 263, "offsetInEndSection": 368, "text": "Therefore, efficient processing of Okazaki fragments is vital for DNA replication and cell proliferation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448"}, {"offsetInBeginSection": 369, "offsetInEndSection": 506, "text": "During this process, primase-synthesized RNA/DNA primers are removed, and Okazaki fragments are joined into an intact lagging strand DNA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448"}, {"offsetInBeginSection": 741, "offsetInEndSection": 819, "text": "Recent findings reveal that Okazaki fragment maturation is highly coordinated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448"}, {"offsetInBeginSection": 820, "offsetInEndSection": 999, "text": "The dynamic interactions of polymerase \u03b4, FEN1 and DNA ligase I with proliferating cell nuclear antigen allow these enzymes to act sequentially during Okazaki fragment maturation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448"}, {"offsetInBeginSection": 1266, "offsetInEndSection": 1400, "text": "Mutations that affect the efficiency of RNA primer removal may result in accumulation of unligated nicks and DNA double-strand breaks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448"}, {"offsetInBeginSection": 1401, "offsetInEndSection": 1582, "text": "These DNA strand breaks can cause varying forms of chromosome aberrations, contributing to development of cancer that associates with aneuploidy and gross chromosomal rearrangement.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448"}, {"offsetInBeginSection": 507, "offsetInEndSection": 629, "text": "The processing of RNA/DNA primers requires a group of structure-specific nucleases typified by flap endonuclease 1 (FEN1).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448"}]}, {"id": "5a68f633b750ff4455000019", "body": "Is creatinine assessment included in the MELD score?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27480755", "http://www.ncbi.nlm.nih.gov/pubmed/15482344", "http://www.ncbi.nlm.nih.gov/pubmed/23293714", "http://www.ncbi.nlm.nih.gov/pubmed/24601755", "http://www.ncbi.nlm.nih.gov/pubmed/22380485", "http://www.ncbi.nlm.nih.gov/pubmed/20827408", "http://www.ncbi.nlm.nih.gov/pubmed/17370333", "http://www.ncbi.nlm.nih.gov/pubmed/22178107", "http://www.ncbi.nlm.nih.gov/pubmed/27779785", "http://www.ncbi.nlm.nih.gov/pubmed/18482269"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Liver dysfunction as predictor of prognosis in patients with amyloidosis: utility of the Model for End-stage Liver disease (MELD) scoring system.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27480755"}, {"offsetInBeginSection": 1271, "offsetInEndSection": 1320, "text": "MELD is able to predict prognosis in amyloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27480755"}, {"offsetInBeginSection": 1321, "offsetInEndSection": 1397, "text": "A MELD score >12 selects a subgroup of patients with a higher risk of death.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27480755"}, {"offsetInBeginSection": 0, "offsetInEndSection": 223, "text": "Can inclusion of serum creatinine values improve the Child-Turcotte-Pugh score and challenge the prognostic yield of the model for end-stage liver disease score in the short-term prognostic assessment of cirrhotic patients?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482344"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "BACKGROUND: The model for end-stage liver disease (MELD) score is a useful tool to assess prognosis in critically ill cirrhotic patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482344"}, {"offsetInBeginSection": 138, "offsetInEndSection": 272, "text": "However, its short-term prognostic superiority over the traditional Child-Turcotte-Pugh (CTP) score has not been definitely confirmed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482344"}, {"offsetInBeginSection": 273, "offsetInEndSection": 371, "text": "The creatinine serum level is an important predictor of survival in patients with liver cirrhosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482344"}, {"offsetInBeginSection": 371, "offsetInEndSection": 530, "text": "AIMS: To evaluate and compare the short-term prognostic accuracy of the CTP, the creatinine-modified CTP, and the MELD scores in patients with liver cirrhosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482344"}, {"offsetInBeginSection": 530, "offsetInEndSection": 639, "text": "METHODS: CTP, creatinine-modified CTP, and MELD scores were calculated in a cohort of 145 cirrhotic patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482344"}, {"offsetInBeginSection": 640, "offsetInEndSection": 861, "text": "The creatinine-modified CTP was calculated as follows: we assessed the mean creatinine serum level and standard deviation (SD) of the 145 study patients, then assigned a score of 1 to patients with creatinine serum levels", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482344"}]}, {"id": "5a6d196db750ff4455000032", "body": "Which resource has been developed in order to study the transcriptional regulation of GABAergic cell fate?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27710791"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Subpallial Enhancer Transgenic Lines: a Data and Tool Resource to Study Transcriptional Regulation of GABAergic Cell Fate.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27710791"}]}, {"id": "5a79d195faa1ab7d2e00000e", "body": "Is celiac disease caused by gliadin-induced transglutaminase-2 (TG2)-dependent events ?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24240659"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Diversity of oat varieties in eliciting the early inflammatory events in celiac disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "PURPOSE: Celiac disease (CD) is an autoimmune enteropathy, triggered by dietary gluten.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659"}, {"offsetInBeginSection": 276, "offsetInEndSection": 451, "text": "The present study examined the capability of different oat cultivars of activating the gliadin-induced transglutaminase-2 (TG2)-dependent events in some in vitro models of CD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659"}, {"offsetInBeginSection": 589, "offsetInEndSection": 819, "text": "METHODS: K562(S) cells agglutination, transepithelial electrical resistance of T84-cell monolayers, intracellular levels of TG2 and phosphorylated form of protein 42-44 in T84 cells were the early gliadin-dependent events studied.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659"}, {"offsetInBeginSection": 942, "offsetInEndSection": 1119, "text": "The ability of a cultivar to activate the above-described events was associated with the electrophoretic pattern of oat proteins and their reactivity to anti-gliadin antibodies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659"}]}, {"id": "5a68f965b750ff445500001a", "body": "Clue cells are characteristics to which causative bacteria of vaginitis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/3497132", "http://www.ncbi.nlm.nih.gov/pubmed/6610607", "http://www.ncbi.nlm.nih.gov/pubmed/12838684", "http://www.ncbi.nlm.nih.gov/pubmed/10932748"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Non-specific vaginitis or vaginitis of undetermined aetiology.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Vaginitis is a complex syndrome that is probably the most common outpatient disease seen by the gynaecologist.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132"}, {"offsetInBeginSection": 111, "offsetInEndSection": 158, "text": "The specific aetiologies of vaginitis are many.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132"}, {"offsetInBeginSection": 159, "offsetInEndSection": 343, "text": "One of the most common entities, however, is \"non-specific vaginitis\" which can be subdivided into: Gardnerella vaginitis, anaerobic vaginosis, and vaginitis of undetermined aetiology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132"}, {"offsetInBeginSection": 344, "offsetInEndSection": 473, "text": "The role of Gardnerella as a causative agent for vaginitis has been studied in depth but its specific role remains controversial.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132"}, {"offsetInBeginSection": 474, "offsetInEndSection": 638, "text": "Anaerobic vaginosis can be diagnosed by noting on microscopic examination the presence of clue cells, free-floating bacteria and numerous white blood cells (WBC's).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132"}, {"offsetInBeginSection": 823, "offsetInEndSection": 999, "text": "Vaginitis of undetermined aetiology is more complex and is characterized by a purulent vaginal discharge, a pH of 4.0-4.6, numerous WBC's, and a high concentration of bacteria.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132"}, {"offsetInBeginSection": 1000, "offsetInEndSection": 1104, "text": "The microbiology of this vaginitis includes many facultative Gram-negative rods and Gram-positive cocci.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132"}, {"offsetInBeginSection": 1197, "offsetInEndSection": 1304, "text": "This condition does not respond to the usual antibiotic therapies employed in treating bacterial vaginitis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132"}, {"offsetInBeginSection": 0, "offsetInEndSection": 56, "text": "Gardnerella-associated vaginitis and anaerobic bacteria.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6610607"}]}, {"id": "5a6d1db1b750ff4455000033", "body": "What is the purpose of the FaceBase consortium?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21458441", "http://www.ncbi.nlm.nih.gov/pubmed/27287806", "http://www.ncbi.nlm.nih.gov/pubmed/26168040"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "The FaceBase Consortium: a comprehensive program to facilitate craniofacial research.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21458441"}, {"offsetInBeginSection": 0, "offsetInEndSection": 255, "text": "The FaceBase Consortium consists of ten interlinked research and technology projects whose goal is to generate craniofacial research data and technology for use by the research community through a central data management and integrated bioinformatics hub.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21458441"}, {"offsetInBeginSection": 256, "offsetInEndSection": 1011, "text": "Funded by the National Institute of Dental and Craniofacial Research (NIDCR) and currently focused on studying the development of the middle region of the face, the Consortium will produce comprehensive datasets of global gene expression patterns, regulatory elements and sequencing; will generate anatomical and molecular atlases; will provide human normative facial data and other phenotypes; conduct follow up studies of a completed genome-wide association study; generate independent data on the genetics of craniofacial development, build repositories of animal models and of human samples and data for community access and analysis; and will develop software tools and animal models for analyzing and functionally testing and integrating these data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21458441"}, {"offsetInBeginSection": 1012, "offsetInEndSection": 1291, "text": "The FaceBase website (http://www.facebase.org) will serve as a web home for these efforts, providing interactive tools for exploring these datasets, together with discussion forums and other services to support and foster collaboration within the craniofacial research community.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21458441"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "The FaceBase Consortium: a comprehensive resource for craniofacial researchers.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27287806"}, {"offsetInBeginSection": 0, "offsetInEndSection": 521, "text": "The FaceBase Consortium, funded by the National Institute of Dental and Craniofacial Research, National Institutes of Health, is designed to accelerate understanding of craniofacial developmental biology by generating comprehensive data resources to empower the research community, exploring high-throughput technology, fostering new scientific collaborations among researchers and human/computer interactions, facilitating hypothesis-driven research and translating science into improved health care to benefit patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27287806"}, {"offsetInBeginSection": 522, "offsetInEndSection": 924, "text": "The resources generated by the FaceBase projects include a number of dynamic imaging modalities, genome-wide association studies, software tools for analyzing human facial abnormalities, detailed phenotyping, anatomical and molecular atlases, global and specific gene expression patterns, and transcriptional profiling over the course of embryonic and postnatal development in animal models and humans.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27287806"}, {"offsetInBeginSection": 925, "offsetInEndSection": 1119, "text": "The integrated data visualization tools, faceted search infrastructure, and curation provided by the FaceBase Hub offer flexible and intuitive ways to interact with these multidisciplinary data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27287806"}, {"offsetInBeginSection": 1120, "offsetInEndSection": 1276, "text": "In parallel, the datasets also offer unique opportunities for new collaborations and training for researchers coming into the field of craniofacial studies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27287806"}, {"offsetInBeginSection": 0, "offsetInEndSection": 40, "text": "Molecular Anatomy of Palate Development.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26168040"}]}, {"id": "5a79d25dfaa1ab7d2e00000f", "body": "Does wheat belongs to the genus Avena, yes or no?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24226111", "http://www.ncbi.nlm.nih.gov/pubmed/8984007", "http://www.ncbi.nlm.nih.gov/pubmed/12669804", "http://www.ncbi.nlm.nih.gov/pubmed/25120168", "http://www.ncbi.nlm.nih.gov/pubmed/10464792", "http://www.ncbi.nlm.nih.gov/pubmed/29083384"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "The genus Avena consists of at least 23 species composed of three ploidy levels.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24226111"}, {"offsetInBeginSection": 183, "offsetInEndSection": 321, "text": "We have isolated a repeated sequence clone that can be used for the detection of the C genome in Avena by filter hybridization techniques.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24226111"}, {"offsetInBeginSection": 322, "offsetInEndSection": 477, "text": "This clone, termed RS-1, is a genomic DNA clone containing at least one highly repeated sequence that is abundant in Avena species containing the C genome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24226111"}, {"offsetInBeginSection": 728, "offsetInEndSection": 812, "text": "We have also done similar analysis of the Avena genus using a rDNA clone from wheat.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24226111"}, {"offsetInBeginSection": 943, "offsetInEndSection": 1103, "text": "These molecular probes can be useful in studying the genomic relationships of Avena and can provide some clues as to the origin of the cultivated Avena species.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24226111"}, {"offsetInBeginSection": 1104, "offsetInEndSection": 1261, "text": "These results can, therefore, provide breeders with directions for the efficient transfer of desirable traits of wild Avena species into commencal varieties.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24226111"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Chromosomal and genomic organization of Ty1-copia-like retrotransposon sequences in the genus Avena.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8984007"}, {"offsetInBeginSection": 297, "offsetInEndSection": 458, "text": "The cloned DNA fragment was a dispersed repeat present in all Avena species used in this study (A. strigosa, A. clauda, A. vaviloviana, A. magna, and A. sativa).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8984007"}, {"offsetInBeginSection": 721, "offsetInEndSection": 967, "text": "In situ hybridization of pAvKB30 to diploid, tetraploid, and hexaploid oat species revealed that the probe is present on both arms of all chromosomes (A, B, C, and D genomes) but is excluded from their centromeric and nucleolar organizer regions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8984007"}, {"offsetInBeginSection": 1164, "offsetInEndSection": 1300, "text": "Furthermore, under low stringency conditions, pAvKB30 hybridized on Southern blots containing barley, wheat, rye, and Arrhenatherum DNA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8984007"}]}, {"id": "5a68fd01b750ff445500001b", "body": "What is included in the fourth generation HIV test?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23984592", "http://www.ncbi.nlm.nih.gov/pubmed/29062724", "http://www.ncbi.nlm.nih.gov/pubmed/28846743", "http://www.ncbi.nlm.nih.gov/pubmed/24342480", "http://www.ncbi.nlm.nih.gov/pubmed/24342477", "http://www.ncbi.nlm.nih.gov/pubmed/16908076", "http://www.ncbi.nlm.nih.gov/pubmed/19320855", "http://www.ncbi.nlm.nih.gov/pubmed/28710996", "http://www.ncbi.nlm.nih.gov/pubmed/25464967", "http://www.ncbi.nlm.nih.gov/pubmed/11595590"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "[Evaluation of an immunochromatographic fourth generation test for the rapid diagnosis of acute HIV infection].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "The early diagnosis of human immunodeficiency virus (HIV) infection is important to provide effective antiviral treatment and to prevent transmission of HIV.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592"}, {"offsetInBeginSection": 372, "offsetInEndSection": 611, "text": "In 2008, the Espline HIV Ag/Ab test kit (E4G, Fujirebio Inc. Japan) was marketed in Japan belonging to the fourth generation of HIV test kits characterized by its ability to detect both viral antigens (Ag) and anti-HIV-1/2 antibodies (Ab).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592"}, {"offsetInBeginSection": 612, "offsetInEndSection": 720, "text": "E4G is the first and only fourth generation immunochromatographic HIV test kit approved in Japan at present.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592"}, {"offsetInBeginSection": 721, "offsetInEndSection": 949, "text": "To evaluate its performance to diagnose acute HIV infection (AHI), E4G was compared with fourth generation Ag/Ab ELISA test kits, a third generation PA test kit, WB and real-time PCR for the testing of 25 AHI clinical specimens.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592"}, {"offsetInBeginSection": 950, "offsetInEndSection": 1125, "text": "E4G detected HIV infection in 18/25 specimens (sensitivity : 72.0%), of which the viral Ag was detected in only 2 specimens (8.0%) bearing a viral load > 10 million copies/mL.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592"}, {"offsetInBeginSection": 1126, "offsetInEndSection": 1198, "text": "No spesimens were simultaneously reactive to both Ag and Ab against HIV.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592"}, {"offsetInBeginSection": 1199, "offsetInEndSection": 1322, "text": "The third generation PA achieved a positive score of 17/ 25 specimens (68.0%), which was almost the same as the E4G figure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592"}, {"offsetInBeginSection": 1323, "offsetInEndSection": 1432, "text": "In contrast the fourth generation Ag/ Ab ELISA scored all the 25 AHI specimens positive (sensitivity : 100%).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592"}, {"offsetInBeginSection": 1433, "offsetInEndSection": 1617, "text": "Overall, although having the merit of offering a rapid diagnostic test for HIV infection, E4G does not provide a sensitivity in AHI diagnosis superior to test kits currently available.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592"}]}, {"id": "5a6d2558b750ff4455000036", "body": "Does Uc.160 promote cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28382457"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Expression and function of Uc.160+, a transcribed ultraconserved region, in gastric cancer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457"}, {"offsetInBeginSection": 400, "offsetInEndSection": 491, "text": "Uc.160+, a T-UCR reported to be downregulated in human cancer, has not been examined in GC.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457"}, {"offsetInBeginSection": 491, "offsetInEndSection": 823, "text": "METHODS: We analyzed the expression pattern of Uc.160+ in nonneoplastic and tumor tissues of the stomach by using uantitative reverse transcription polymerase chain reaction (qRT-PCR) and in situ hybridization (ISH), specifically focusing on the mechanism of transcriptional regulation and target genes that are regulated by T-UCRs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457"}, {"offsetInBeginSection": 824, "offsetInEndSection": 948, "text": "We also attempted to determine the effect of Uc.160+ expression on biological features of GC cell lines by Western blotting.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457"}, {"offsetInBeginSection": 1140, "offsetInEndSection": 1263, "text": "Cancer-specific DNA methylation in the promoter region of Uc.160 was observed by bisulfite genomic DNA sequencing analysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457"}, {"offsetInBeginSection": 1264, "offsetInEndSection": 1361, "text": "The effect of DNA methylation on Uc.160+ expression was further confirmed by reporter gene assay.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457"}, {"offsetInBeginSection": 1362, "offsetInEndSection": 1492, "text": "We also revealed that Uc.160+ inhibited the phosphorylation of Akt by regulating phosphatase and tensin homolog (PTEN) expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457"}, {"offsetInBeginSection": 1492, "offsetInEndSection": 1592, "text": "CONCLUSIONS: These results indicate that Uc.160+ could possibly have a tumor suppressive role in GC.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457"}]}, {"id": "5a8712af61bb38fb24000002", "body": "What is the link between psoriatic arthritis and depression", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21794775", "http://www.ncbi.nlm.nih.gov/pubmed/27258525", "http://www.ncbi.nlm.nih.gov/pubmed/27221798", "http://www.ncbi.nlm.nih.gov/pubmed/28507445", "http://www.ncbi.nlm.nih.gov/pubmed/19151962", "http://www.ncbi.nlm.nih.gov/pubmed/24407907", "http://www.ncbi.nlm.nih.gov/pubmed/23908539", "http://www.ncbi.nlm.nih.gov/pubmed/22015150", "http://www.ncbi.nlm.nih.gov/pubmed/28733473", "http://www.ncbi.nlm.nih.gov/pubmed/28320454"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "[Prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21794775"}, {"offsetInBeginSection": 113, "offsetInEndSection": 281, "text": "The aim of the study was to assess the prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics.PATIENTS AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21794775"}, {"offsetInBeginSection": 359, "offsetInEndSection": 556, "text": "Patients with psoriatic arthritis were recruited; variables retrieved were sociodemographic, clinical and patient centered (Hospital Anxiety and Depression scale o HADs, EQ-5D questionnaire, etc.).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21794775"}, {"offsetInBeginSection": 557, "offsetInEndSection": 707, "text": "Prevalence in the study population was calculated as anxiety or depression symptoms by an HADs score \u226511 or those receiving pharmacological treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21794775"}, {"offsetInBeginSection": 928, "offsetInEndSection": 1024, "text": "Prevalence of symptoms of anxiety were 29.7% and prevalence of symptoms of depression was 17,6%.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21794775"}, {"offsetInBeginSection": 1025, "offsetInEndSection": 1106, "text": "Patients with anxiety or depression symptoms had all EQ-5D dimensions affected (p", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21794775"}, {"offsetInBeginSection": 1106, "offsetInEndSection": 1275, "text": "CONCLUSION: The prevalence of anxiety symptoms and the prevalence of depression symptoms are high among patients suffering psoriatic arthritis in the studied population.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21794775"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Depression and Insomnia in Patients With Psoriasis and Psoriatic Arthritis Taking Tumor Necrosis Factor Antagonists.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27258525"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Psoriasis patients with moderate to severe disease often present with depression and insomnia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27258525"}, {"offsetInBeginSection": 95, "offsetInEndSection": 445, "text": "Treatment targeting both psoriasis and psychological comorbidities is needed to improve the quality of life of these patients.In this nationwide cohort study, a total of 980 patients with psoriatic arthritis or psoriasis who had received nonbiological disease-modifying antirheumatic drugs and biologics therapy between 2009 and 2012 were identified.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27258525"}]}, {"id": "5a6900ebb750ff445500001d", "body": "Which disease is diagnosed using the Finkelstein's test?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15680568", "http://www.ncbi.nlm.nih.gov/pubmed/23340762", "http://www.ncbi.nlm.nih.gov/pubmed/12723309", "http://www.ncbi.nlm.nih.gov/pubmed/26538761", "http://www.ncbi.nlm.nih.gov/pubmed/15792200", "http://www.ncbi.nlm.nih.gov/pubmed/1402284", "http://www.ncbi.nlm.nih.gov/pubmed/10070674"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 45, "text": "Finkelstein's test: a biomechanical analysis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15680568"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "PURPOSE: Finkelstein's test is the classic diagnostic test for de Quervain's disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15680568"}, {"offsetInBeginSection": 86, "offsetInEndSection": 333, "text": "Finkelstein hypothesized that the entry of the muscle bellies of the extensor pollicis brevis (EPB) and abductor pollicis longus (APL) tendons into the first extensor compartment was responsible for the findings observed in his now eponymous test.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15680568"}, {"offsetInBeginSection": 334, "offsetInEndSection": 559, "text": "We agree with Finkelstein's hypothesis and further hypothesize that this position would induce measurable bulk (muscle mass within the retinaculum) and tethering (stretching of synovial tissue) effects within the compartment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15680568"}, {"offsetInBeginSection": 560, "offsetInEndSection": 696, "text": "To test this latter hypothesis we measured the excursion and gliding resistance of the EPB and APL tendons within the first compartment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15680568"}, {"offsetInBeginSection": 1542, "offsetInEndSection": 1746, "text": "CONCLUSIONS: We showed that in the position of Finkelstein's test the EPB tendon is significantly more distal and has significantly greater bulk and tethering effect compared with the other EPB positions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15680568"}, {"offsetInBeginSection": 1747, "offsetInEndSection": 1825, "text": "This is not the case for the APL tendon in the position of Finkelstein's test.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15680568"}, {"offsetInBeginSection": 1826, "offsetInEndSection": 1942, "text": "These results suggest that an abnormal Finkelstein's test reflects differences of the EPB more than it does the APL.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15680568"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "The wrist hyperflexion and abduction of the thumb (WHAT) test: a more specific and sensitive test to diagnose de Quervain tenosynovitis than the Eichhoff's Test.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23340762"}, {"offsetInBeginSection": 0, "offsetInEndSection": 54, "text": "De Quervain's disease has different clinical features.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23340762"}]}, {"id": "5a6e1280b750ff4455000037", "body": "For which type of cancer can uc.189 be used as a potential prognostic biomarker?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28941722"], "snippets": [{"offsetInBeginSection": 104, "offsetInEndSection": 255, "text": "Until now, the role of the UCE uc.189 in human cancers remains undefined and the clinical significance of uc.189 in esophageal cancers remains unknown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722"}, {"offsetInBeginSection": 372, "offsetInEndSection": 572, "text": "Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression level of uc.189 in matched cancerous tissues and adjacent noncancerous tissues from 152 patients with ESCC.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Ultraconserved elements (UCEs) encoding noncoding RNAs serve as important regulators in cancer biology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722"}]}, {"id": "5a87140a61bb38fb24000003", "body": "What is Chronic Wasting Disease (CWD) in deer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27575545", "http://www.ncbi.nlm.nih.gov/pubmed/17553219", "http://www.ncbi.nlm.nih.gov/pubmed/12680636", "http://www.ncbi.nlm.nih.gov/pubmed/16439622", "http://www.ncbi.nlm.nih.gov/pubmed/27711208", "http://www.ncbi.nlm.nih.gov/pubmed/17020952", "http://www.ncbi.nlm.nih.gov/pubmed/18387626", "http://www.ncbi.nlm.nih.gov/pubmed/28193766", "http://www.ncbi.nlm.nih.gov/pubmed/17092889", "http://www.ncbi.nlm.nih.gov/pubmed/15542685"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Chronic Wasting Disease Drives Population Decline of White-Tailed Deer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27575545"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Chronic wasting disease (CWD) is an invariably fatal transmissible spongiform encephalopathy of white-tailed deer, mule deer, elk, and moose.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27575545"}, {"offsetInBeginSection": 142, "offsetInEndSection": 317, "text": "Despite a 100% fatality rate, areas of high prevalence, and increasingly expanding geographic endemic areas, little is known about the population-level effects of CWD in deer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27575545"}, {"offsetInBeginSection": 318, "offsetInEndSection": 473, "text": "To investigate these effects, we tested the null hypothesis that high prevalence CWD did not negatively impact white-tailed deer population sustainability.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27575545"}, {"offsetInBeginSection": 474, "offsetInEndSection": 684, "text": "The specific objectives of the study were to monitor CWD-positive and CWD-negative white-tailed deer in a high-prevalence CWD area longitudinally via radio-telemetry and global positioning system (GPS) collars.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27575545"}, {"offsetInBeginSection": 1060, "offsetInEndSection": 1278, "text": "Survival was significantly lower for CWD-positive deer and separately by sex; CWD-positive deer were 4.5 times more likely to die annually than CWD-negative deer while bucks were 1.7 times more likely to die than does.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27575545"}, {"offsetInBeginSection": 1357, "offsetInEndSection": 1629, "text": "We show that a chronic disease that becomes endemic in wildlife populations has the potential to be population-limiting and the strong population-level effects of CWD suggest affected populations are not sustainable at high disease prevalence under current harvest levels.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27575545"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Levels of abnormal prion protein in deer and elk with chronic wasting disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17553219"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Chronic wasting disease (CWD) of deer and elk is a widespread health concern because its potential for crossspecies transmission is undetermined.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17553219"}, {"offsetInBeginSection": 146, "offsetInEndSection": 312, "text": "CWD prevalence in wild elk is much lower than its prevalence in wild deer, and whether CWD-infected deer and elk differ in ability to infect other species is unknown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17553219"}]}, {"id": "5a69031bb750ff445500001e", "body": "Can doxycycline cause photosensitivity?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9214073", "http://www.ncbi.nlm.nih.gov/pubmed/17160610", "http://www.ncbi.nlm.nih.gov/pubmed/26299894", "http://www.ncbi.nlm.nih.gov/pubmed/10233667", "http://www.ncbi.nlm.nih.gov/pubmed/21879777", "http://www.ncbi.nlm.nih.gov/pubmed/23182067", "http://www.ncbi.nlm.nih.gov/pubmed/17315050", "http://www.ncbi.nlm.nih.gov/pubmed/3684731", "http://www.ncbi.nlm.nih.gov/pubmed/15262663", "http://www.ncbi.nlm.nih.gov/pubmed/26189561"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 39, "text": "[Doxycycline induced photoonycholysis].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9214073"}, {"offsetInBeginSection": 87, "offsetInEndSection": 189, "text": "Tetracyclines are known to provoke photosensitivity reactions in some individuals exposed to sunlight.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9214073"}, {"offsetInBeginSection": 305, "offsetInEndSection": 531, "text": "With travel to regions with sunny climates it will be important to be aware of the risk of developing onycholysis following the use of tetracyclines and to avoid the most potential phototoxic derivates, especially doxycycline.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9214073"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Doxycycline versus ceftriaxone for the treatment of patients with chronic Lyme borreliosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17160610"}, {"offsetInBeginSection": 1388, "offsetInEndSection": 1540, "text": "Photosensitivity reactions and gastrointestinal symptoms were noted more often among patients receiving doxycycline than in those receiving ceftriaxone.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17160610"}, {"offsetInBeginSection": 1541, "offsetInEndSection": 1616, "text": "Treatment with doxycycline proved to be much cheaper than with ceftriaxone.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17160610"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Doxycycline assay hair samples for testing long-term compliance treatment.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26299894"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "OBJECTIVES: Many patients undergoing long-term doxycycline treatment do not regularly take their treatment because of photosensitivity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26299894"}, {"offsetInBeginSection": 603, "offsetInEndSection": 758, "text": "We tested 14 patients treated with doxycycline and we found similar levels of doxycycline in the serum and the hair samples representing the last 4 months.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26299894"}, {"offsetInBeginSection": 759, "offsetInEndSection": 1014, "text": "Linear regression analysis revealed that the level of doxycycline in the serum remained stable over time (p = 0.7) but the level of doxycycline in the hair decreased significantly over time (p = 0.03) indicating a degradation of this molecule in the hair.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26299894"}]}, {"id": "5a6e21b4b750ff445500003a", "body": "Are paralog genes co-regulated?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18493055", "http://www.ncbi.nlm.nih.gov/pubmed/27634932", "http://www.ncbi.nlm.nih.gov/pubmed/20621981", "http://www.ncbi.nlm.nih.gov/pubmed/20660482"], "snippets": [{"offsetInBeginSection": 511, "offsetInEndSection": 839, "text": "By analyzing paralogs of testis-biased genes, we identified \"co-regulated\" paralogous pairs in which both genes are testis biased, \"anti-regulated\" pairs in which one paralog is testis biased and the other downregulated in testes, and \"neutral\" pairs in which one paralog is testis biased and the other constitutively expressed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18493055"}, {"offsetInBeginSection": 840, "offsetInEndSection": 940, "text": "The numbers of identified co-regulated and anti-regulated pairs were higher than expected by chance.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18493055"}, {"offsetInBeginSection": 1240, "offsetInEndSection": 1489, "text": "Further, interspecific changes in testis bias of expression are generally correlated within the co-regulated pairs and are anti-correlated within the anti-regulated pairs, suggesting coordinated regulation within both types of paralogous gene pairs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18493055"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Co-regulation of paralog genes in the three-dimensional chromatin architecture.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27634932"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "Paralog genes arise from gene duplication events during evolution, which often lead to similar proteins that cooperate in common pathways and in protein complexes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27634932"}, {"offsetInBeginSection": 164, "offsetInEndSection": 278, "text": "Consequently, paralogs show correlation in gene expression whereby the mechanisms of co-regulation remain unclear.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27634932"}, {"offsetInBeginSection": 279, "offsetInEndSection": 399, "text": "In eukaryotes, genes are regulated in part by distal enhancer elements through looping interactions with gene promoters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27634932"}, {"offsetInBeginSection": 923, "offsetInEndSection": 1129, "text": "We show that paralog gene pairs are enriched for co-localization in the same TAD, share more often common enhancer elements than expected and have increased contact frequencies over large genomic distances.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27634932"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Meta-analysis of cancer gene expression signatures reveals new cancer genes, SAGE tags and tumor associated regions of co-regulation.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20621981"}, {"offsetInBeginSection": 289, "offsetInEndSection": 459, "text": "Our methodology, which we denote 'COgnate Gene Expression patterNing in tumours' (COGENT), unmasked numerous genes that were differentially expressed in multiple cancers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20621981"}]}, {"id": "5a87145861bb38fb24000004", "body": "What causes Black Lung?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2933965", "http://www.ncbi.nlm.nih.gov/pubmed/17300721", "http://www.ncbi.nlm.nih.gov/pubmed/16304297", "http://www.ncbi.nlm.nih.gov/pubmed/28450031", "http://www.ncbi.nlm.nih.gov/pubmed/2806196", "http://www.ncbi.nlm.nih.gov/pubmed/17516558", "http://www.ncbi.nlm.nih.gov/pubmed/16497850", "http://www.ncbi.nlm.nih.gov/pubmed/26437452", "http://www.ncbi.nlm.nih.gov/pubmed/7810543", "http://www.ncbi.nlm.nih.gov/pubmed/11170158"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Compensation for occupational disease with multiple causes: the case of coal miners' respiratory diseases.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2933965"}, {"offsetInBeginSection": 279, "offsetInEndSection": 519, "text": "Conflicting definitions of terms--coal workers' pneumoconiosis as defined by the medical profession, pneumoconiosis as defined by the United States Congress, and the popular term, black lung--are important considerations in this discussion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2933965"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Many diseases associated with occupational exposures are clinically indistinguishable from diseases with non-occupational causes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2933965"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Black tea prevents cigarette smoke-induced apoptosis and lung damage.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17300721"}, {"offsetInBeginSection": 136, "offsetInEndSection": 191, "text": "Oxidative stress may lead to apoptosis and lung injury.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17300721"}, {"offsetInBeginSection": 192, "offsetInEndSection": 374, "text": "Since black tea has antioxidant property, we examined the preventive effect of black tea on cigarette smoke-induced oxidative damage, apoptosis and lung injury in a guinea pig model.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17300721"}, {"offsetInBeginSection": 627, "offsetInEndSection": 746, "text": "Lung damage, as evidenced by inflammation and increased air space, was assessed by histology and morphometric analysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17300721"}, {"offsetInBeginSection": 1068, "offsetInEndSection": 1143, "text": "RESULTS: Cigarette smoke exposure to a guinea pig model caused lung damage.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17300721"}, {"offsetInBeginSection": 1144, "offsetInEndSection": 1263, "text": "It appeared that oxidative stress was the initial event, which was followed by inflammation, apoptosis and lung injury.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17300721"}, {"offsetInBeginSection": 1420, "offsetInEndSection": 1595, "text": "CONCLUSION: Cigarette smoke exposure to a guinea pig model causes oxidative damage, inflammation, apoptosis and lung injury that are prevented by supplementation of black tea.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17300721"}]}, {"id": "5a6f7e6ab750ff4455000052", "body": "List four principles of medical ethics.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11794075", "http://www.ncbi.nlm.nih.gov/pubmed/14519842", "http://www.ncbi.nlm.nih.gov/pubmed/7463428", "http://www.ncbi.nlm.nih.gov/pubmed/26793677", "http://www.ncbi.nlm.nih.gov/pubmed/23975951", "http://www.ncbi.nlm.nih.gov/pubmed/15183570", "http://www.ncbi.nlm.nih.gov/pubmed/21625670", "http://www.ncbi.nlm.nih.gov/pubmed/25516952", "http://www.ncbi.nlm.nih.gov/pubmed/16731739"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Teaching medical ethics in Basra: perspective of students and graduates.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11794075"}, {"offsetInBeginSection": 810, "offsetInEndSection": 928, "text": "Only 6% of both graduates and students were able to list the four principles of medical ethics as described by Raanan.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11794075"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Ethics needs principles--four can encompass the rest--and respect for autonomy should be \"first among equals\".", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14519842"}, {"offsetInBeginSection": 0, "offsetInEndSection": 228, "text": "It is hypothesised and argued that \"the four principles of medical ethics\" can explain and justify, alone or in combination, all the substantive and universalisable claims of medical ethics and probably of ethics more generally.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14519842"}, {"offsetInBeginSection": 229, "offsetInEndSection": 454, "text": "A request is renewed for falsification of this hypothesis showing reason to reject any one of the principles or to require any additional principle(s) that can't be explained by one or some combination of the four principles.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14519842"}, {"offsetInBeginSection": 0, "offsetInEndSection": 50, "text": "A philosophy of a clinically based medical ethics.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7463428"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Pellegrino and Siegler have argued that medical ethics must be taught 'at the bedside', or clinically.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7463428"}, {"offsetInBeginSection": 103, "offsetInEndSection": 263, "text": "This paper is an attempt to establish the need for clinical teaching of medical ethics both to medical students and to medical ethicists who are not physicians.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7463428"}, {"offsetInBeginSection": 264, "offsetInEndSection": 438, "text": "Through a critique of six positions regarding the aims of medical ethics, four principles are established which are the basis of a philosophy of education for medical ethics.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7463428"}, {"offsetInBeginSection": 439, "offsetInEndSection": 593, "text": "The need for a clinically-based educational programme in medical ethics is thereby established, not on practical grounds, but on solid philosophical ones.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7463428"}]}, {"id": "5a6e22b9b750ff445500003b", "body": "What is CellMaps?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27296979"], "snippets": []}, {"id": "5a8714e261bb38fb24000005", "body": "Is polyadenylation a process that stabilizes a protein by adding a string of Adenosine residues to the end of the molecule?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2408761", "http://www.ncbi.nlm.nih.gov/pubmed/9933592", "http://www.ncbi.nlm.nih.gov/pubmed/3037325", "http://www.ncbi.nlm.nih.gov/pubmed/16467265", "http://www.ncbi.nlm.nih.gov/pubmed/3019671", "http://www.ncbi.nlm.nih.gov/pubmed/2160581", "http://www.ncbi.nlm.nih.gov/pubmed/9242905", "http://www.ncbi.nlm.nih.gov/pubmed/11557765", "http://www.ncbi.nlm.nih.gov/pubmed/12270133", "http://www.ncbi.nlm.nih.gov/pubmed/9223284"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "Accurate cleavage and polyadenylation of exogenous RNA substrate.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2408761"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "Purified precursor RNA containing the L3 polyadenylation site of late adenovirus 2 mRNA is accurately cleaved and polyadenylated when incubated with nuclear extract from HeLa cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2408761"}, {"offsetInBeginSection": 368, "offsetInEndSection": 434, "text": "Additional adenosine residues are added during further incubation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2408761"}, {"offsetInBeginSection": 767, "offsetInEndSection": 861, "text": "Fingerprint analysis suggests this RNA is produced by endonucleolytic cleavage at the L3 site.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2408761"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Polyadenylation promotes degradation of 3'-structured RNA by the Escherichia coli mRNA degradosome in vitro.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9933592"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Polyadenylation contributes to the destabilization of bacterial mRNA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9933592"}, {"offsetInBeginSection": 70, "offsetInEndSection": 199, "text": "We have investigated the role of polyadenylation in the degradation of RNA by the purified Escherichia coli degradosome in vitro.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9933592"}, {"offsetInBeginSection": 745, "offsetInEndSection": 817, "text": "Addition of a 3'-poly(A) tail stimulated degradation by the degradosome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9933592"}, {"offsetInBeginSection": 940, "offsetInEndSection": 1151, "text": "The data show that the degradosome requires a single-stranded \"toehold\" 3' to a secondary structure to recognize and degrade the RNA molecule efficiently; polyadenylation can provide this single-stranded 3'-end.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9933592"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Products of in vitro cleavage and polyadenylation of simian virus 40 late pre-mRNAs.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3037325"}]}, {"id": "5a6f829eb750ff4455000054", "body": "Can multiple myeloma patients develop hyperviscosity syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7699907", "http://www.ncbi.nlm.nih.gov/pubmed/2385441", "http://www.ncbi.nlm.nih.gov/pubmed/22827791", "http://www.ncbi.nlm.nih.gov/pubmed/9046114", "http://www.ncbi.nlm.nih.gov/pubmed/26623375", "http://www.ncbi.nlm.nih.gov/pubmed/694674", "http://www.ncbi.nlm.nih.gov/pubmed/14631546", "http://www.ncbi.nlm.nih.gov/pubmed/5415687", "http://www.ncbi.nlm.nih.gov/pubmed/1201229", "http://www.ncbi.nlm.nih.gov/pubmed/17315105"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 26, "text": "[Hyperviscosity syndrome].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7699907"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Common clinical manifestations of the hyperviscosity syndrome are bleeding from mucosal membrane, retinopathy, visual disturbance and neurological disorders.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7699907"}, {"offsetInBeginSection": 246, "offsetInEndSection": 421, "text": "Five to 10 percent of patients with multiple myeloma are suffered from the hyperviscosity syndrome because of increased serum viscosity due to the presence of myeloma protein.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7699907"}, {"offsetInBeginSection": 520, "offsetInEndSection": 744, "text": "Plasmapheresis is known as an efficient method for rapid improvement of the hyperviscosity syndrome, and double filtration plasmapheresis is most commonly used for plasma exchange of multiple myeloma patients in our country.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7699907"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "IgA myeloma complicated by fractures of the bones and hyperviscosity syndrome--report of an autopsied case.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2385441"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "A case of IgA (kappa type) myeloma complicated by fractures of the bones and hyperviscosity syndrome is presented.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2385441"}, {"offsetInBeginSection": 115, "offsetInEndSection": 244, "text": "A 56-year-old woman who had been followed as an outpatient with diabetes mellitus for about 16 years, developed multiple myeloma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2385441"}, {"offsetInBeginSection": 457, "offsetInEndSection": 614, "text": "At autopsy, almost all bones showed infiltration of multiple myeloma of IgA-kappa type and severe osteoporosis accompanied with proliferation of osteoclasts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2385441"}, {"offsetInBeginSection": 615, "offsetInEndSection": 713, "text": "The association of IgA myeloma with hyperviscosity syndrome and/or bone destruction was discussed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2385441"}, {"offsetInBeginSection": 714, "offsetInEndSection": 863, "text": "The \"serum hyperviscosity syndrome\" has been described clinically as the triad of bleeding, visual signs and symptoms, and neurologic manifestations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2385441"}]}, {"id": "5a6e2578b750ff445500003d", "body": "Which package in Bioconductor has been developed with the aim to analyze differential DNA loops from sequencing data?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22847932", "http://www.ncbi.nlm.nih.gov/pubmed/29028898", "http://www.ncbi.nlm.nih.gov/pubmed/27008016", "http://www.ncbi.nlm.nih.gov/pubmed/24227674", "http://www.ncbi.nlm.nih.gov/pubmed/24979058", "http://www.ncbi.nlm.nih.gov/pubmed/27347386", "http://www.ncbi.nlm.nih.gov/pubmed/26834993", "http://www.ncbi.nlm.nih.gov/pubmed/26578583", "http://www.ncbi.nlm.nih.gov/pubmed/29052185", "http://www.ncbi.nlm.nih.gov/pubmed/26819470"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "easyRNASeq: a bioconductor package for processing RNA-Seq data.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "MOTIVATION: RNA sequencing is becoming a standard for expression profiling experiments and many tools have been developed in the past few years to analyze RNA-Seq data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932"}, {"offsetInBeginSection": 169, "offsetInEndSection": 270, "text": "Numerous 'Bioconductor' packages are available for next-generation sequencing data loading in R, e.g.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932"}, {"offsetInBeginSection": 271, "offsetInEndSection": 360, "text": "ShortRead and Rsamtools as well as to perform differential gene expression analyses, e.g.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932"}, {"offsetInBeginSection": 378, "offsetInEndSection": 496, "text": "However, the processing tasks lying in between these require the precise interplay of many Bioconductor packages, e.g.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932"}, {"offsetInBeginSection": 556, "offsetInEndSection": 744, "text": "RESULTS: We developed 'easyRNASeq', an R package that simplifies the processing of RNA sequencing data, hiding the complex interplay of the required packages behind a single functionality.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932"}, {"offsetInBeginSection": 744, "offsetInEndSection": 873, "text": "AVAILABILITY: The package is implemented in R (as of version 2.15) and is available from Bioconductor (as of version 2.10) at the", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932"}, {"offsetInBeginSection": 874, "offsetInEndSection": 1002, "text": "URL: http://bioconductor.org/packages/release/bioc/html/easyRNASeq.html, where installation and usage instructions can be found.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "diffloop: a computational framework for identifying and analyzing differential DNA loops from sequencing data.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028898"}, {"offsetInBeginSection": 289, "offsetInEndSection": 540, "text": "To systematically assess changes in DNA looping architecture between samples, we introduce diffloop, an R/Bioconductor package that provides a suite of functions for the quality control, statistical testing, annotation, and visualization of DNA loops.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028898"}]}, {"id": "5a8715a961bb38fb24000006", "body": "Silent Allosteric Modulation of mGluR5 is a form of treatment for what disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28683325"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer's Mouse Phenotypes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683325"}, {"offsetInBeginSection": 184, "offsetInEndSection": 393, "text": "We used a potent mGluR5 silent allosteric modulator (SAM, BMS-984923) to separate its well-known physiological role in glutamate signaling from a pathological role in mediating amyloid-\u03b2 oligomer (A\u03b2o) action.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683325"}]}, {"id": "5a6f853ab750ff4455000055", "body": "Which disease can be diagnosed with the \"probe to bone\" test?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7853630", "http://www.ncbi.nlm.nih.gov/pubmed/27369321", "http://www.ncbi.nlm.nih.gov/pubmed/21219428", "http://www.ncbi.nlm.nih.gov/pubmed/17259493", "http://www.ncbi.nlm.nih.gov/pubmed/7770390", "http://www.ncbi.nlm.nih.gov/pubmed/24356116", "http://www.ncbi.nlm.nih.gov/pubmed/18601422", "http://www.ncbi.nlm.nih.gov/pubmed/19141236", "http://www.ncbi.nlm.nih.gov/pubmed/1922909", "http://www.ncbi.nlm.nih.gov/pubmed/19485522"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 41, "text": "Probing to bone in infected pedal ulcers.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7853630"}, {"offsetInBeginSection": 70, "offsetInEndSection": 202, "text": "DESIGN: We prospectively assessed infected pedal ulcers for detectable bone by probing with a sterile, blunt, stainless steel probe.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7853630"}, {"offsetInBeginSection": 203, "offsetInEndSection": 363, "text": "We then examined the relationship between detection of bone and the presence or absence of osteomyelitis that was defined histopathologically and/or clinically.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7853630"}, {"offsetInBeginSection": 395, "offsetInEndSection": 502, "text": "PATIENTS: Seventy-five hospitalized diabetic patients with a total of 76 infected foot ulcers were studied.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7853630"}, {"offsetInBeginSection": 595, "offsetInEndSection": 764, "text": "Bone was detected by probing in 33 of 50 ulcers with contiguous osteomyelitis; in contrast, bone was probed in only four of 26 ulcers without contiguous osteomyelitis (P", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7853630"}, {"offsetInBeginSection": 931, "offsetInEndSection": 1057, "text": "If bone is palpated on probing, specialized roentgenographic and radionuclide tests to diagnose osteomyelitis are unnecessary.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7853630"}, {"offsetInBeginSection": 1058, "offsetInEndSection": 1172, "text": "Probing for bone should be included in the initial assessment of all diabetic patients with infected pedal ulcers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7853630"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Diagnostic Accuracy of Probe to Bone to Detect Osteomyelitis in the Diabetic Foot: A Systematic Review.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27369321"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "The probe-to-bone (PTB) test is a commonly used clinical test for osteomyelitis (OM), but its utility has been questioned in clinical settings where the prevalence of OM is low.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27369321"}, {"offsetInBeginSection": 602, "offsetInEndSection": 744, "text": "Pooled sensitivity and specificity for the PTB test was 0.87 (95% confidence interval [CI], .75-.93) and 0.83 (95% CI, .65-.93), respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27369321"}]}, {"id": "5a6e33e4b750ff4455000041", "body": "Describe annotatr", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28369316"], "snippets": []}, {"id": "5a8718c861bb38fb24000008", "body": "What are check point inhibitors?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27528363", "http://www.ncbi.nlm.nih.gov/pubmed/26775673", "http://www.ncbi.nlm.nih.gov/pubmed/28878676", "http://www.ncbi.nlm.nih.gov/pubmed/28865357", "http://www.ncbi.nlm.nih.gov/pubmed/27403706"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528363"}, {"offsetInBeginSection": 488, "offsetInEndSection": 570, "text": "OBJECTIVE: To clarify the role of immune check point inhibitors in GBM management.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528363"}, {"offsetInBeginSection": 570, "offsetInEndSection": 769, "text": "METHODS: Preclinical and clinical trials of immune check-point inhibitors in GBM were obtained by searching for English peer-reviewed articles on PubMed databases, trials registered on clincaltrials.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528363"}, {"offsetInBeginSection": 835, "offsetInEndSection": 972, "text": "RESULTS: Immune check point inhibitors may be of critical importance for the design of future immunotherapy approaches in GBM management.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528363"}, {"offsetInBeginSection": 972, "offsetInEndSection": 1071, "text": "CONCLUSION: Immune check-point inhibitors should be considered a promising treatment option in GBM.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528363"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26775673"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "BACKGROUND: We performed a meta-analysis of the risk of endocrine adverse events associated with immune check point inhibitors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26775673"}, {"offsetInBeginSection": 539, "offsetInEndSection": 766, "text": "CONCLUSION: Our meta-analysis has demonstrated that the use of immune check point inhibitors is associated with an increased risk of hypothyroidism, hyperthyroidism, hypophysitis and adrenal insufficiency compared with control.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26775673"}, {"offsetInBeginSection": 236, "offsetInEndSection": 423, "text": "Check point antibody inhibitors, such as anti-PD-1/PD-L1, are a novel class of inhibitors that function as a tumor suppressing factor via modulation of immune cell-tumor cell interaction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28878676"}, {"offsetInBeginSection": 588, "offsetInEndSection": 715, "text": "In recent times, more than four check point antibody inhibitors have been commercialized for targeting PD-1, PDL-1, and CTLA-4.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28878676"}]}, {"id": "5a6f87c5b750ff4455000056", "body": "Are patients with Sjogren syndrome at increased risk for lymphoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27336863", "http://www.ncbi.nlm.nih.gov/pubmed/17562045", "http://www.ncbi.nlm.nih.gov/pubmed/16462517", "http://www.ncbi.nlm.nih.gov/pubmed/25368273", "http://www.ncbi.nlm.nih.gov/pubmed/2110929", "http://www.ncbi.nlm.nih.gov/pubmed/24159176", "http://www.ncbi.nlm.nih.gov/pubmed/20084442", "http://www.ncbi.nlm.nih.gov/pubmed/12064854", "http://www.ncbi.nlm.nih.gov/pubmed/24153350", "http://www.ncbi.nlm.nih.gov/pubmed/1608349"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Predicting the risk for lymphoma development in Sjogren syndrome: An easy tool for clinical use.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27336863"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "The heightened risk of non-Hodgkin lymphoma (NHL) development in primary Sjogren syndrome (SS) is well established.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27336863"}, {"offsetInBeginSection": 363, "offsetInEndSection": 586, "text": "In the present case-control study of 381 primary SS patients and 92 primary SS patients with concomitant NHL, clinical, serological, and histopathological variables at the time of SS diagnosis were retrospectively recorded.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27336863"}, {"offsetInBeginSection": 697, "offsetInEndSection": 959, "text": "Salivary gland enlargement (SGE), lymphadenopathy, Raynaud phenomenon, anti-Ro/SSA or/and anti-La/SSB autoantibodies, rheumatoid factor (RF) positivity, monoclonal gammopathy, and C4 hypocomplementemia were shown to be independent predictors for NHL development.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27336863"}, {"offsetInBeginSection": 1087, "offsetInEndSection": 1245, "text": "Thus, patients presenting with \u22642 risk factors had a 3.8% probability of NHL development, those with 3 to 6 risk factors 39.9% (OR (95%CI): 16.6 [6.5-42.5], P", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27336863"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Family history of lymphoma and risk for solid tumors in patients with Sjogren's syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17562045"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "It has been recognized that primary Sjogren's syndrome predisposes to the development of lymphoproliferative disorders.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17562045"}, {"offsetInBeginSection": 120, "offsetInEndSection": 217, "text": "However, it is so far uncertain whether these patients are at an increased risk for solid tumors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17562045"}, {"offsetInBeginSection": 218, "offsetInEndSection": 383, "text": "Herein we report two cases of primary Sjogren's syndrome complicated by breast and lung cancer and who have a strong family history for lymphoproliferative diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17562045"}, {"offsetInBeginSection": 206, "offsetInEndSection": 356, "text": "Evidence has been accumulating recently in rheumatoid arthritis, Sjogren's syndrome, systemic lupus erythematosus, and scleroderma/systemic sclerosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16462517"}]}, {"id": "5a6e3d21b750ff4455000043", "body": "What is BBCAnalyzer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28241736"], "snippets": []}, {"id": "5a871a6861bb38fb24000009", "body": "What disease is the ALK tyrosine kinase associated with?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27573755", "http://www.ncbi.nlm.nih.gov/pubmed/20223922", "http://www.ncbi.nlm.nih.gov/pubmed/25407901", "http://www.ncbi.nlm.nih.gov/pubmed/25351247", "http://www.ncbi.nlm.nih.gov/pubmed/18923525", "http://www.ncbi.nlm.nih.gov/pubmed/21829174", "http://www.ncbi.nlm.nih.gov/pubmed/27217763", "http://www.ncbi.nlm.nih.gov/pubmed/23714228", "http://www.ncbi.nlm.nih.gov/pubmed/23154552", "http://www.ncbi.nlm.nih.gov/pubmed/26811689"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 47, "text": "The role of the ALK receptor in cancer biology.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "A vast array of oncogenic variants has been identified for anaplastic lymphoma kinase (ALK).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755"}, {"offsetInBeginSection": 93, "offsetInEndSection": 217, "text": "Therefore, there is a need to better understand the role of ALK in cancer biology in order to optimise treatment strategies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755"}, {"offsetInBeginSection": 218, "offsetInEndSection": 393, "text": "This review summarises the latest research on the receptor tyrosine kinase ALK, and how this information can guide the management of patients with cancer that is ALK-positive.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755"}, {"offsetInBeginSection": 537, "offsetInEndSection": 817, "text": "A wide variety of ALK fusions, in which the kinase domain of ALK and the amino-terminal portion of various protein partners are fused, occur in cancer, with echinoderm microtubule-associated protein-like 4 (EML4)-ALK being the most prevalent in non-small-cell lung cancer (NSCLC).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755"}, {"offsetInBeginSection": 818, "offsetInEndSection": 969, "text": "Different ALK fusion proteins can mediate different signalling outputs, depending on properties such as subcellular localisation and protein stability.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755"}, {"offsetInBeginSection": 1103, "offsetInEndSection": 1273, "text": "Two ALK tyrosine kinase inhibitors (TKIs), crizotinib and ceritinib, are currently approved in Europe for use in ALK-positive NSCLC and several others are in development.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755"}, {"offsetInBeginSection": 1274, "offsetInEndSection": 1465, "text": "These ALK TKIs bind slightly differently within the ATP-binding pocket of the ALK kinase domain and are associated with the emergence of different resistance mutation patterns during therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755"}, {"offsetInBeginSection": 1466, "offsetInEndSection": 1573, "text": "This emphasises the need to tailor the sequence of ALK TKIs according to the ALK signature of each patient.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755"}, {"offsetInBeginSection": 1574, "offsetInEndSection": 1739, "text": "Research into the oncogenic functions of ALK, and fast paced development of ALK inhibitors, has substantially improved outcomes for patients with ALK-positive NSCLC.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755"}]}, {"id": "5a6f8dc6b750ff4455000058", "body": "Is trastuzumab associated cardiotoxicity reversible?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26836985", "http://www.ncbi.nlm.nih.gov/pubmed/19669637", "http://www.ncbi.nlm.nih.gov/pubmed/24905295", "http://www.ncbi.nlm.nih.gov/pubmed/18514938", "http://www.ncbi.nlm.nih.gov/pubmed/21310845", "http://www.ncbi.nlm.nih.gov/pubmed/15177418", "http://www.ncbi.nlm.nih.gov/pubmed/18484781", "http://www.ncbi.nlm.nih.gov/pubmed/23282614", "http://www.ncbi.nlm.nih.gov/pubmed/14613026", "http://www.ncbi.nlm.nih.gov/pubmed/19147689"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26836985"}, {"offsetInBeginSection": 158, "offsetInEndSection": 252, "text": "As a paradox in cancer survivors, delayed cardiotoxicity has emerged as a significant problem.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26836985"}, {"offsetInBeginSection": 253, "offsetInEndSection": 562, "text": "Two categories of cardiotoxic side effects of antineoplastic drugs have been previously proposed: Type I cardiotoxicity, defined as permanent cardiotoxicity, is usually caused by anthracyclines; Type II cardiotoxicity, considered as reversible cardiotoxicity, has been mainly related to monoclonal antibodies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26836985"}, {"offsetInBeginSection": 563, "offsetInEndSection": 837, "text": "The cardiotoxicity of antibodies has been associated to trastuzumab, a humanized anti-ErbB2 monoclonal antibody currently in clinical use for the therapy of breast carcinomas, which induces cardiac dysfunction when used in monotherapy, or in combination with anthracyclines.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26836985"}, {"offsetInBeginSection": 1156, "offsetInEndSection": 1306, "text": "On the other hand, early detection and prompt therapy of anthracycline associated cardiotoxicity can lead to substantial recovery of cardiac function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26836985"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19669637"}, {"offsetInBeginSection": 0, "offsetInEndSection": 286, "text": "INTRODUCTION: Although having high clinical efficacy in the treatment of human epidermal growth factor receptor-2 (HER2+) metastatic breast cancer, trastuzumab has been associated with cardiotoxicity, and the etiology and pathogenesis of this condition is currently under investigation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19669637"}, {"offsetInBeginSection": 286, "offsetInEndSection": 438, "text": "METHODS: This paper reviews the cardiotoxicity, associated with trastuzumab use and discusses the risk assessment and management of cardiac dysfunction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19669637"}, {"offsetInBeginSection": 438, "offsetInEndSection": 599, "text": "RESULTS: The increased risk of cardiotoxicity is lower when trastuzumab is given as monotherapy (3%-7%) compared with anthracyclines + trastuzumab therapy (27%).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19669637"}, {"offsetInBeginSection": 600, "offsetInEndSection": 778, "text": "Type II cardiac changes occur in trastuzumab-treated patients, which do not appear to be dose-related, are not associated with histological changes, and are generally reversible.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19669637"}]}, {"id": "5a6e3fe3b750ff4455000044", "body": "Does the human lncRNA LINC-PINT promote tumorigenesis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29078818"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "The human lncRNA LINC-PINT inhibits tumor cell invasion through a highly conserved sequence element.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "BACKGROUND: It is now obvious that the majority of cellular transcripts do not code for proteins, and a significant subset of them are long non-coding RNAs (lncRNAs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818"}, {"offsetInBeginSection": 274, "offsetInEndSection": 403, "text": "However, the underlying mechanisms remain poorly understood and it is unknown how the sequences of lncRNA dictate their function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818"}, {"offsetInBeginSection": 403, "offsetInEndSection": 500, "text": "RESULTS: Here we characterize the function of the p53-regulated human lncRNA LINC-PINT in cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818"}, {"offsetInBeginSection": 501, "offsetInEndSection": 658, "text": "We find that LINC-PINT is downregulated in multiple types of cancer and acts as a tumor suppressor lncRNA by reducing the invasive phenotype of cancer cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818"}, {"offsetInBeginSection": 659, "offsetInEndSection": 779, "text": "A cross-species analysis identifies a highly conserved sequence element in LINC-PINT that is essential for its function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818"}, {"offsetInBeginSection": 780, "offsetInEndSection": 966, "text": "This sequence mediates a specific interaction with PRC2, necessary for the LINC-PINT-dependent repression of a pro-invasion signature of genes regulated by the transcription factor EGR1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818"}]}, {"id": "5a871b8d61bb38fb2400000a", "body": "What body process does the Dentate Gyrus Mossy Cell control?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18189312", "http://www.ncbi.nlm.nih.gov/pubmed/9187278", "http://www.ncbi.nlm.nih.gov/pubmed/17765742", "http://www.ncbi.nlm.nih.gov/pubmed/14999076", "http://www.ncbi.nlm.nih.gov/pubmed/10531454", "http://www.ncbi.nlm.nih.gov/pubmed/1308178", "http://www.ncbi.nlm.nih.gov/pubmed/18077687", "http://www.ncbi.nlm.nih.gov/pubmed/24811867", "http://www.ncbi.nlm.nih.gov/pubmed/7721998", "http://www.ncbi.nlm.nih.gov/pubmed/11043552"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Calretinin expression in hilar mossy cells of the hippocampal dentate gyrus of nonhuman primates and humans.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18189312"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "Mossy cells, the major excitatory neurons of the hilus of the dentate gyrus constitutively express calretinin in several rodent species, including mouse and hamster, but not in rats.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18189312"}, {"offsetInBeginSection": 183, "offsetInEndSection": 385, "text": "Several studies suggest that mossy cells of the monkey dentate gyrus are calretinin-positive, but others have reported mossy cells in monkeys to be devoid of detectable calretinin-like immunoreactivity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18189312"}, {"offsetInBeginSection": 580, "offsetInEndSection": 774, "text": "In the examined four monkey species, mossy cells were found to be calretinin-positive at the uncal pole and at variable length within the main body of the dentate gyrus but not in the tail part.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18189312"}, {"offsetInBeginSection": 775, "offsetInEndSection": 1099, "text": "The associational pathway, formed by axons of mossy cells in the inner dentate molecular layer was calretinin-positive in more caudal sections, suggesting that mossy cell axon terminals may contain calretinin, whereas mossy cell somata may contain calretinin in a concentration too low to be detected by immunocytochemistry.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18189312"}, {"offsetInBeginSection": 1100, "offsetInEndSection": 1228, "text": "In contrast, human mossy cells appear to be devoid of calretinin immunoreactivity in both their somata and their axon terminals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18189312"}, {"offsetInBeginSection": 1229, "offsetInEndSection": 1461, "text": "Taken together, mossy cells of nonhuman primates and humans exhibit different expression pattern for calretinin whereas they show similarities in neurochemical content, such as the cocaine and amphetamine-related transcript peptide.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18189312"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Septal innervation of mossy cells in the hilus of the rat dentate gyrus: an anterograde tracing and intracellular labeling study.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9187278"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Mossy cells in the hilus of the rat dentate gyrus are the main cells of origin of the dentate commissural and associational projections.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9187278"}, {"offsetInBeginSection": 137, "offsetInEndSection": 279, "text": "They project along the septotemporal axis of the dentate gyrus and may thus influence the hippocampal signal flow in a longitudinal direction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9187278"}]}, {"id": "5a6f922fb750ff4455000059", "body": "Can canagliflozin cause euglycemic diabetic ketoacidosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27375734", "http://www.ncbi.nlm.nih.gov/pubmed/28090050", "http://www.ncbi.nlm.nih.gov/pubmed/27928503", "http://www.ncbi.nlm.nih.gov/pubmed/28634592", "http://www.ncbi.nlm.nih.gov/pubmed/27088018"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375734"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "We are reporting a timely case of atypical euglycemic diabetic ketoacidosis in a type 1 diabetic patient treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitor canagliflozin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375734"}, {"offsetInBeginSection": 364, "offsetInEndSection": 507, "text": "Ketoacidosis resolved after increasing dextrose and insulin doses supporting the hypothesis that SGLT-2 inhibitors may lead to hypoinsulinemia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375734"}, {"offsetInBeginSection": 508, "offsetInEndSection": 595, "text": "Euglycemic ketoacidosis did not recur in our patient after discontinuing canagliflozin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375734"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28090050"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Diabetic ketoacidosis is characterized by hyperglycemia, anion-gap acidosis, and increased plasma ketones.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28090050"}, {"offsetInBeginSection": 175, "offsetInEndSection": 442, "text": "We herein report the case of a 27-year-old Asian woman with type 2 diabetes who was treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor (canagliflozin) who developed euglycemic diabetic ketoacidosis and persistent diuresis in the absence of hyperglycemia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28090050"}, {"offsetInBeginSection": 443, "offsetInEndSection": 575, "text": "Physicians should consider euglycemic diabetic ketoacidosis in the differential diagnosis of patients treated with SGLT2 inhibitors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28090050"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Metabolic ketoacidosis with normal blood glucose: A rare complication of sodium-glucose cotransporter 2 inhibitors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27928503"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "Ketoacidosis is a significant and often a life-threatening complication of diabetes mellitus seen mostly in type 1 diabetes mellitus as well as occasionally in type 2 diabetes mellitus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27928503"}]}, {"id": "5a6e4136b750ff4455000045", "body": "Describe the Match BAM to VCF (MBV) method.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28186259"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "MBV: a method to solve sample mislabeling and detect technical bias in large combined genotype and sequencing assay datasets.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28186259"}, {"offsetInBeginSection": 0, "offsetInEndSection": 714, "text": "Motivation: Large genomic datasets combining genotype and sequence data, such as for expression quantitative trait loci (eQTL) detection, require perfect matching between both data types.Results: We described here MBV (Match BAM to VCF); a method to quickly solve sample mislabeling and detect cross-sample contamination and PCR amplification bias.Availability and Implementation: MBV is implemented in C\u2009++\u2009as an independent component of the QTLtools software package, the binary and source codes are freely available at https://qtltools.github.io/qtltools/ .Contact: olivier.delaneau@unige.ch or emmanouil.dermitzakis@unige.ch.Supplementary information: Supplementary data are available at Bioinformatics online.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28186259"}]}, {"id": "5a897601fcd1d6a10c000008", "body": "A SLEDAI score is associated with Systemic Lupus Erythematosus. What is a SLEDAI score?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10685800", "http://www.ncbi.nlm.nih.gov/pubmed/19762400", "http://www.ncbi.nlm.nih.gov/pubmed/22516994", "http://www.ncbi.nlm.nih.gov/pubmed/27365721", "http://www.ncbi.nlm.nih.gov/pubmed/23172751", "http://www.ncbi.nlm.nih.gov/pubmed/17477466", "http://www.ncbi.nlm.nih.gov/pubmed/16354890", "http://www.ncbi.nlm.nih.gov/pubmed/23647447", "http://www.ncbi.nlm.nih.gov/pubmed/8235662", "http://www.ncbi.nlm.nih.gov/pubmed/11480850"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Accurately describing changes in disease activity in Systemic Lupus Erythematosus.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "OBJECTIVE: To determine whether Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores correlate with the clinician's impression of level of disease activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800"}, {"offsetInBeginSection": 171, "offsetInEndSection": 319, "text": "METHODS: In total, 230 patients with SLE followed at the University of Toronto Lupus Clinic who had 5 visits 3 months apart in 1992-93 were studied.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800"}, {"offsetInBeginSection": 369, "offsetInEndSection": 503, "text": "A clinician who did not know the patients or their SLEDAI scores evaluated each patient record and assigned a clinical activity level.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800"}, {"offsetInBeginSection": 651, "offsetInEndSection": 701, "text": "The SLEDAI score was calculated from the database.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800"}, {"offsetInBeginSection": 701, "offsetInEndSection": 794, "text": "RESULTS: SLEDAI scores described a range of clinical activity as recognized by the clinician.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800"}, {"offsetInBeginSection": 795, "offsetInEndSection": 885, "text": "Median SLEDAI scores ranged from 2 (inactive disease) to 8 (persistently active or flare).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800"}, {"offsetInBeginSection": 886, "offsetInEndSection": 981, "text": "When the clinician assessed the patient to be improved, the median SLEDAI score decreased by 2.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800"}, {"offsetInBeginSection": 1097, "offsetInEndSection": 1178, "text": "CONCLUSION: Based on our data we propose the following outcomes for patients with", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800"}, {"offsetInBeginSection": 1179, "offsetInEndSection": 1346, "text": "SLE: flare, an increase in SLEDAI > 3; improvement is a reduction in SLEDAI of > 3; persistently active disease is change in SLEDAI +/- 3; and remission a SLEDAI of 0.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800"}]}, {"id": "5a6f941eb750ff445500005b", "body": "What is the association between kidney donation risk of gestational complications?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27591246", "http://www.ncbi.nlm.nih.gov/pubmed/26090646", "http://www.ncbi.nlm.nih.gov/pubmed/18798006", "http://www.ncbi.nlm.nih.gov/pubmed/22252087", "http://www.ncbi.nlm.nih.gov/pubmed/26558022", "http://www.ncbi.nlm.nih.gov/pubmed/12351541", "http://www.ncbi.nlm.nih.gov/pubmed/26895841", "http://www.ncbi.nlm.nih.gov/pubmed/19353771", "http://www.ncbi.nlm.nih.gov/pubmed/27271097", "http://www.ncbi.nlm.nih.gov/pubmed/15240849"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 203, "text": "Communicating the current knowledge of medical outcomes after live kidney donation necessary to support donor candidates in well informed decision-making requires grounding in perspectives of comparison.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27591246"}, {"offsetInBeginSection": 204, "offsetInEndSection": 326, "text": "Baseline risk (without donating), risk attributable to donation, and absolute risk (after donating) need to be considered.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27591246"}, {"offsetInBeginSection": 327, "offsetInEndSection": 439, "text": "Severe perioperative complications and death are rare, but vary by demographic, clinical, and procedure factors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27591246"}, {"offsetInBeginSection": 831, "offsetInEndSection": 964, "text": "Pregnancies in donors may incur attributable risk of gestational hypertension or preeclampsia (11% versus 5% incidence in one study).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27591246"}, {"offsetInBeginSection": 965, "offsetInEndSection": 1152, "text": "A modest rise in uric acid levels beginning early after donation, and a small (1.4%) increase in the 8-year incidence of gout, have also been reported in comparisons to healthy nondonors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27591246"}, {"offsetInBeginSection": 0, "offsetInEndSection": 58, "text": "Living kidney donation: outcomes, ethics, and uncertainty.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26090646"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Since the first living-donor kidney transplantation in 1954, more than half a million living kidney donations have occurred and research has advanced knowledge about long-term donor outcomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26090646"}, {"offsetInBeginSection": 296, "offsetInEndSection": 419, "text": "Living kidney donation is associated with an increased risk of end-stage renal disease, although this outcome is uncommon (", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26090646"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Assessment of the knowledge of living unrelated donors of the complications of kidney donation in Iran.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18798006"}, {"offsetInBeginSection": 262, "offsetInEndSection": 411, "text": "This study evaluated the knowledge of donors about possible short- and long-term complications of kidney donation and the need for regular follow-up.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18798006"}]}, {"id": "5a6e4592b750ff4455000047", "body": "What is the 959 Nematode Genomes initiative?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24058822", "http://www.ncbi.nlm.nih.gov/pubmed/22044053"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 28, "text": "Toward 959 nematode genomes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24058822"}, {"offsetInBeginSection": 370, "offsetInEndSection": 518, "text": "The phylum Nematoda is rich and diverse and of interest to a wide range of research fields from basic biology through ecology and parasitic disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24058822"}, {"offsetInBeginSection": 1003, "offsetInEndSection": 1194, "text": "To inspire, promote and coordinate genomic sequencing across the diversity of the phylum, we have launched a community wiki and the 959 Nematode Genomes initiative (www.nematodegenomes.org/).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24058822"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "The diversity of biology in nematodes is reflected in the diversity of their genomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044053"}, {"offsetInBeginSection": 86, "offsetInEndSection": 246, "text": "Parasitic species in particular have evolved mechanisms to invade and outwit their hosts, and these offer opportunities for the development of control measures.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044053"}, {"offsetInBeginSection": 1379, "offsetInEndSection": 1459, "text": "These efforts are being coordinated through the 959 Nematode Genomes initiative.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044053"}]}, {"id": "5a897927fcd1d6a10c00000a", "body": "What does A1C measure?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20923490", "http://www.ncbi.nlm.nih.gov/pubmed/18030866", "http://www.ncbi.nlm.nih.gov/pubmed/16336550", "http://www.ncbi.nlm.nih.gov/pubmed/23990520", "http://www.ncbi.nlm.nih.gov/pubmed/18509211", "http://www.ncbi.nlm.nih.gov/pubmed/28843470", "http://www.ncbi.nlm.nih.gov/pubmed/22301123", "http://www.ncbi.nlm.nih.gov/pubmed/24511995", "http://www.ncbi.nlm.nih.gov/pubmed/20861123", "http://www.ncbi.nlm.nih.gov/pubmed/28964455"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 50, "text": "Does A1c consistently reflect mean plasma glucose?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20923490"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "One size does not fit all: the need for a continuous measure for glycemic control in diabetes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18030866"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "BACKGROUND: The assessment of glycemic control, most commonly using glycosylated hemoglobin (A1C), has been a major measure for care of patients with diabetes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18030866"}, {"offsetInBeginSection": 1248, "offsetInEndSection": 1392, "text": "CONCLUSIONS: A continuous measure of A1C can better capture than a dichotomous measure the complexity of glycemic control at a population level.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18030866"}, {"offsetInBeginSection": 962, "offsetInEndSection": 1040, "text": "MEASURE: Monthly change in A1c for average patient cared for at each facility.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16336550"}, {"offsetInBeginSection": 1837, "offsetInEndSection": 2014, "text": "We propose that evaluation of change in A1c levels over time can be used as a new measure to reflect quality of care provided to populations of individuals with chronic disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16336550"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Mitigating case mix factors by choice of glycemic control performance measure threshold.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18509211"}, {"offsetInBeginSection": 250, "offsetInEndSection": 457, "text": "We assessed differences in A1C performance measure threshold attainment by case mix factors for A1C >9% and examined how lowering the threshold to A1C >8% or >7% changed these differences.RESEARCH DESIGN AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18509211"}, {"offsetInBeginSection": 1283, "offsetInEndSection": 1427, "text": "Reporting by diabetes medication use may compensate for heterogeneous case mix when a performance measure threshold of A1C >8% or lower is used.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18509211"}, {"offsetInBeginSection": 729, "offsetInEndSection": 984, "text": "RESULTS: Among 253 dyads, the frequencies of patients compared to caregivers who could accurately describe what the A1C level assesses, identify the ideal A1C target, and identify the ideal BG range were 20 vs. 66, 31 vs. 56, and 72 vs. 76%, respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28843470"}]}, {"id": "5a6f98e6b750ff445500005d", "body": "Which ligament is most commonly injured in dashboard injury?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/3425783", "http://www.ncbi.nlm.nih.gov/pubmed/7377448", "http://www.ncbi.nlm.nih.gov/pubmed/22890899", "http://www.ncbi.nlm.nih.gov/pubmed/27623865", "http://www.ncbi.nlm.nih.gov/pubmed/15062581", "http://www.ncbi.nlm.nih.gov/pubmed/15474227", "http://www.ncbi.nlm.nih.gov/pubmed/20110155", "http://www.ncbi.nlm.nih.gov/pubmed/18980604", "http://www.ncbi.nlm.nih.gov/pubmed/21257845", "http://www.ncbi.nlm.nih.gov/pubmed/19468882"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 58, "text": "Isolated posterior cruciate ligament injuries in athletes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3425783"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "The literature is divided as to the necessity of an intact posterior cruciate ligament for functional stability.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3425783"}, {"offsetInBeginSection": 254, "offsetInEndSection": 353, "text": "The diagnosis of posterior cruciate ligament tear was made clinically and confirmed by arthroscopy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3425783"}, {"offsetInBeginSection": 354, "offsetInEndSection": 393, "text": "The average age at injury was 22 years.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3425783"}, {"offsetInBeginSection": 394, "offsetInEndSection": 437, "text": "The athletic activity at injury was varied.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3425783"}, {"offsetInBeginSection": 438, "offsetInEndSection": 574, "text": "Hyperflexion was the most common mechanism of injury, followed by pretibial trauma in the hyperflexed knee or in the \"dashboard\" injury.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3425783"}, {"offsetInBeginSection": 644, "offsetInEndSection": 732, "text": "Direct visualization of the posterior cruciate ligament was not attained in one patient.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3425783"}, {"offsetInBeginSection": 912, "offsetInEndSection": 1028, "text": "All patients were able to return to their previous activity and experienced no limitations with their injured knees.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3425783"}, {"offsetInBeginSection": 1294, "offsetInEndSection": 1458, "text": "Nonoperative treatment of the isolated posterior cruciate ligament midsubstance injury may be a viable alternative to the difficult repair/reconstruction procedure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3425783"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Occult knee ligament injuries associated with femoral shaft fractures.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7377448"}]}, {"id": "5a6e49a4b750ff445500004b", "body": "Is LDB1-mediated enhancer looping dependent on cohesin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28520978"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "LDB1-mediated enhancer looping can be established independent of mediator and cohesin.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978"}, {"offsetInBeginSection": 282, "offsetInEndSection": 450, "text": "Here we tested the contributions of the RNA Pol II pre-initiation complex (PIC), mediator and cohesin to establishment of locus control region (LCR)/\u03b2-globin proximity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978"}, {"offsetInBeginSection": 780, "offsetInEndSection": 1018, "text": "To separate the roles of LDB1 and mediator in LCR looping, we expressed a looping-competent but transcription-activation deficient form of LDB1 in LDB1 knock down cells: LCR/\u03b2-globin proximity was restored without mediator core occupancy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978"}, {"offsetInBeginSection": 1167, "offsetInEndSection": 1359, "text": "Moreover, ENCODE data and our chromatin immunoprecipitation results indicate that cohesin is almost completely absent from validated and predicted LDB1-regulated erythroid enhancer-gene pairs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978"}, {"offsetInBeginSection": 1360, "offsetInEndSection": 1488, "text": "Thus, lineage specific factors largely mediate enhancer-promoter looping in erythroid cells independent of mediator and cohesin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978"}]}, {"id": "5a897a06fcd1d6a10c00000b", "body": "What is the normal body temperature in dogs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/495147", "http://www.ncbi.nlm.nih.gov/pubmed/25854787", "http://www.ncbi.nlm.nih.gov/pubmed/2759725", "http://www.ncbi.nlm.nih.gov/pubmed/28216687", "http://www.ncbi.nlm.nih.gov/pubmed/21102554", "http://www.ncbi.nlm.nih.gov/pubmed/22058348", "http://www.ncbi.nlm.nih.gov/pubmed/9656028", "http://www.ncbi.nlm.nih.gov/pubmed/11913416", "http://www.ncbi.nlm.nih.gov/pubmed/19575699", "http://www.ncbi.nlm.nih.gov/pubmed/6617751"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "On the mechanism of central effect of thyroxine on body temperature in dogs.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/495147"}, {"offsetInBeginSection": 0, "offsetInEndSection": 250, "text": "The effect of intraventricular injection of thyroxine 1 microgram/animal on body temperature was studied in dogs under resting conditions: at normal ambient temperature, at high ambient temperature (35 degrees C) and during administration of pyrogen.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/495147"}, {"offsetInBeginSection": 251, "offsetInEndSection": 355, "text": "Besides, changes in body temperature were elucidated in dogs performing physical exercise following I.V.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/495147"}, {"offsetInBeginSection": 387, "offsetInEndSection": 486, "text": "Thyroxine exerted its central action on body temperature only in dogs performing physical exercise.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/495147"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "Measurement of body temperature in 300 dogs with a novel noncontact infrared thermometer on the cornea in comparison to a standard rectal digital thermometer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25854787"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "OBJECTIVE: To assess the accuracy of obtaining body temperatures in dogs with a noncontact infrared thermometer (NCIT) on the cornea compared with a rectal digital thermometer (RDT).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25854787"}, {"offsetInBeginSection": 260, "offsetInEndSection": 342, "text": "ANIMALS: Three hundred dogs presented with low, normal, or high body temperatures.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25854787"}, {"offsetInBeginSection": 342, "offsetInEndSection": 509, "text": "INTERVENTIONS: Three body temperature readings were measured by an RDT and by an NCIT on the cornea of the left eye by 2 investigators (experienced and inexperienced).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25854787"}, {"offsetInBeginSection": 580, "offsetInEndSection": 799, "text": "RESULTS: Median body temperature measured by the experienced investigator with the RDT and the NCIT were 38.3\u00b0C (range 35.5\u00b0C-41.1\u00b0C; 95% CI: 38.2-38.4\u00b0C) and 37.7\u00b0C (35.9\u00b0C-40.1\u00b0C; 95% CI: 37.7\u00b0C-37.9\u00b0C), respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25854787"}, {"offsetInBeginSection": 1061, "offsetInEndSection": 1150, "text": "CONCLUSIONS: There was poor agreement between body temperatures obtained by RDT and NCIT.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25854787"}]}, {"id": "5a70d12899e2c3af26000001", "body": "List symptoms of Heerfordt syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17637529", "http://www.ncbi.nlm.nih.gov/pubmed/20184241", "http://www.ncbi.nlm.nih.gov/pubmed/18454397", "http://www.ncbi.nlm.nih.gov/pubmed/22565854", "http://www.ncbi.nlm.nih.gov/pubmed/25087562", "http://www.ncbi.nlm.nih.gov/pubmed/26885424", "http://www.ncbi.nlm.nih.gov/pubmed/25685372", "http://www.ncbi.nlm.nih.gov/pubmed/2307892", "http://www.ncbi.nlm.nih.gov/pubmed/21706840", "http://www.ncbi.nlm.nih.gov/pubmed/27549672"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 48, "text": "Sarcoidosis (Heerfordt syndrome): a case report.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17637529"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "We report the case of a 22-year-old woman who is suspected of having primary Sj\u00f6gren s syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17637529"}, {"offsetInBeginSection": 302, "offsetInEndSection": 400, "text": "Sj\u00f6gren s syndrome was suspected at that stage, and the serologic and specific analysis were done.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17637529"}, {"offsetInBeginSection": 401, "offsetInEndSection": 528, "text": "All these tests didn t find any autoimmune or visceral features typical of Sj\u00f6gren s syndrome and autoantibodies were negative.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17637529"}, {"offsetInBeginSection": 771, "offsetInEndSection": 897, "text": "This case demonstrates the importance of being aware of the leading clinical signs and symptoms in case of Heerfordt syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17637529"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "[A case of familial sarcoidosis accompanied by Heerfordt syndrome with pericardial effusion].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20184241"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "We found no cases of familial sarcoidosis with Heerfordt syndrome in the literature.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20184241"}, {"offsetInBeginSection": 358, "offsetInEndSection": 450, "text": "Four months later she came to our hospital complaining of glare, then uveitis was diagnosed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20184241"}, {"offsetInBeginSection": 638, "offsetInEndSection": 693, "text": "Various clinical symptoms indicated Heerfordt syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20184241"}, {"offsetInBeginSection": 749, "offsetInEndSection": 803, "text": "In addition, her sister also suffers from sarcoidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20184241"}]}, {"id": "5a6e4b72b750ff445500004c", "body": "Is there any link between ERCC1-XPF and cohesin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28368372", "http://www.ncbi.nlm.nih.gov/pubmed/14512883", "http://www.ncbi.nlm.nih.gov/pubmed/20518486", "http://www.ncbi.nlm.nih.gov/pubmed/24158589", "http://www.ncbi.nlm.nih.gov/pubmed/14706347", "http://www.ncbi.nlm.nih.gov/pubmed/10882712", "http://www.ncbi.nlm.nih.gov/pubmed/12509251", "http://www.ncbi.nlm.nih.gov/pubmed/11160918", "http://www.ncbi.nlm.nih.gov/pubmed/12202770", "http://www.ncbi.nlm.nih.gov/pubmed/15199134"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "ERCC1-XPF cooperates with CTCF and cohesin to\u00a0facilitate the developmental silencing of imprinted\u00a0genes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Inborn defects in DNA repair are associated with complex developmental disorders whose causal mechanisms are poorly understood.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372"}, {"offsetInBeginSection": 128, "offsetInEndSection": 521, "text": "Using an in vivo biotinylation tagging approach in mice, we show that the nucleotide excision repair (NER) structure-specific endonuclease ERCC1-XPF complex interacts with the insulator binding protein CTCF, the cohesin subunits SMC1A and SMC3 and with MBD2; the factors co-localize with ATRX at the promoters and control regions (ICRs) of imprinted genes during postnatal hepatic development.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372"}, {"offsetInBeginSection": 805, "offsetInEndSection": 1050, "text": "We propose that ERCC1-XPF cooperates with CTCF and cohesin to facilitate the developmental silencing of imprinted genes and that persistent DNA damage triggers chromatin changes that affect gene expression programs associated with NER disorders.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Characterization of premature liver polyploidy in DNA repair (Ercc1)-deficient mice.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14512883"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "ERCC1-XPF is the endonuclease that cuts 5' of the damage in nucleotide excision repair (NER).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14512883"}, {"offsetInBeginSection": 94, "offsetInEndSection": 211, "text": "Unlike other NER proteins, ERCC1-XPF is also involved in recombination and the repair of DNA interstrand cross-links.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14512883"}, {"offsetInBeginSection": 212, "offsetInEndSection": 327, "text": "Unique among the NER gene knockouts, Ercc1 null mice are severely runted with high levels of hepatocyte polyploidy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14512883"}, {"offsetInBeginSection": 328, "offsetInEndSection": 522, "text": "To understand the link between DNA repair deficiency and polyploidy we have compared the premature polyploidy in Ercc1 null liver with the normal development of polyploidy in aging control mice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14512883"}, {"offsetInBeginSection": 1010, "offsetInEndSection": 1211, "text": "We suggest that the more rapid accumulation of DNA damage in Ercc1 null liver leads to an increase in p21 levels, but that there is not a simple direct link between p21 levels and premature polyploidy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14512883"}]}, {"id": "5a8afbf2fcd1d6a10c00001c", "body": "In quadruped mammals, what bones make up the stifle?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17266668", "http://www.ncbi.nlm.nih.gov/pubmed/19378290", "http://www.ncbi.nlm.nih.gov/pubmed/21113010", "http://www.ncbi.nlm.nih.gov/pubmed/19378269", "http://www.ncbi.nlm.nih.gov/pubmed/24323904", "http://www.ncbi.nlm.nih.gov/pubmed/25709597", "http://www.ncbi.nlm.nih.gov/pubmed/23554931", "http://www.ncbi.nlm.nih.gov/pubmed/16226434", "http://www.ncbi.nlm.nih.gov/pubmed/23977887", "http://www.ncbi.nlm.nih.gov/pubmed/3218668"], "snippets": [{"offsetInBeginSection": 224, "offsetInEndSection": 568, "text": "Canine, ovine and equine stifles and human knees were dissected to identify the presence of MFLs, their obliquity in relation to the caudal cruciate ligaments (CCL), the relative size and shape of the MFLs compared with the CCL, the points of femoral attachment of the MFLs and CCL, and the distance between the MFLs and CCL at their midpoints.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17266668"}, {"offsetInBeginSection": 569, "offsetInEndSection": 668, "text": "The lateral tibial condyle was divided sagittally with a handsaw and the caudal slope was measured.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17266668"}, {"offsetInBeginSection": 1179, "offsetInEndSection": 1233, "text": "The caudal tibial slope was steeper in the quadrupeds.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17266668"}, {"offsetInBeginSection": 1234, "offsetInEndSection": 1358, "text": "In the stifle joints of quadrupeds, the MFL is a substantial structure and appears to be related to the caudal tibial slope.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17266668"}, {"offsetInBeginSection": 1359, "offsetInEndSection": 1454, "text": "It is known to resist caudal translation of the tibia in conjunction with the lateral meniscus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17266668"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Comparative anatomy of the meniscofemoral ligament in humans and some domestic mammals.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17266668"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Olecranon orientation as an indicator of elbow joint angle in the stance phase, and estimation of forelimb posture in extinct quadruped animals.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378290"}, {"offsetInBeginSection": 431, "offsetInEndSection": 574, "text": "This study presents a procedure that how the elbow joint angles of extinct quadruped mammals can be inferred from osteological characteristics.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378290"}, {"offsetInBeginSection": 835, "offsetInEndSection": 918, "text": "At this angle, the major extensor muscles maximize their torque at the elbow joint.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378290"}, {"offsetInBeginSection": 919, "offsetInEndSection": 1127, "text": "Based on this survey, I suggest that olecranon orientation can be used for inferring the elbow joint angles of quadruped mammals with prominent olecranons, regardless of taxon, body size, and locomotor guild.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378290"}]}, {"id": "5a70d42899e2c3af26000002", "body": "Mutation of which gene causes arterial tortuosity syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18818946", "http://www.ncbi.nlm.nih.gov/pubmed/18774132", "http://www.ncbi.nlm.nih.gov/pubmed/16550171", "http://www.ncbi.nlm.nih.gov/pubmed/19622975", "http://www.ncbi.nlm.nih.gov/pubmed/22488877", "http://www.ncbi.nlm.nih.gov/pubmed/22734312", "http://www.ncbi.nlm.nih.gov/pubmed/19028722", "http://www.ncbi.nlm.nih.gov/pubmed/19781076", "http://www.ncbi.nlm.nih.gov/pubmed/17935213", "http://www.ncbi.nlm.nih.gov/pubmed/20735855"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "A novel non-sense mutation in the SLC2A10 gene of an arterial tortuosity syndrome patient of Kurdish origin.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18818946"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "Arterial tortuosity syndrome (ATS) is a rare autosomal recessive disorder in which patients display tortuosity of arteries in addition to hyperextensible skin, joint laxity, and other connective tissue features.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18818946"}, {"offsetInBeginSection": 270, "offsetInEndSection": 478, "text": "In this article we describe an ATS girl of Kurdish origin who, in addition to arterial tortuosity and connective tissue features, displays stomach displacement within the thorax and bilateral hip dislocation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18818946"}, {"offsetInBeginSection": 655, "offsetInEndSection": 743, "text": "This mutation in the SLC2A10 gene replaces a cysteine encoding codon with a stop signal.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18818946"}, {"offsetInBeginSection": 828, "offsetInEndSection": 1041, "text": "We conclude that patients of Kurdish origin who display arterial tortuosity associated with skin hyperextensibility, joint hypermobility, and characteristic facial features may carry mutations in the SLC2A10 gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18818946"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "A novel missense and a recurrent mutation in SLC2A10 gene of patients affected with arterial tortuosity syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18774132"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Arterial tortuosity syndrome is an autosomal recessive disorder characterized by severe tortuosity of greater and systemic arteries in affected individuals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18774132"}, {"offsetInBeginSection": 157, "offsetInEndSection": 309, "text": "In addition, patients display connective tissue features which include hyperextensible skin, hypermobility of joints and characteristic facial features.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18774132"}, {"offsetInBeginSection": 310, "offsetInEndSection": 425, "text": "This syndrome is caused by mutation in SLC2A10 gene which encodes for the facilitative glucose transporter, GLUT10.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18774132"}, {"offsetInBeginSection": 426, "offsetInEndSection": 617, "text": "We describe seven patients of two unrelated Saudi Arabian families who display tortuosity, dilatation and stenosis of arteries, pulmonary hypertension and other cardiovascular manifestations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18774132"}]}, {"id": "5a6f940bb750ff445500005a", "body": "What is the aim of the 4D nucleome project?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28905911", "http://www.ncbi.nlm.nih.gov/pubmed/29168505"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 24, "text": "The 4D nucleome project.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28905911"}, {"offsetInBeginSection": 0, "offsetInEndSection": 245, "text": "The 4D Nucleome Network aims to develop and apply approaches to map the structure and dynamics of the human and mouse genomes in space and time with the goal of gaining deeper mechanistic insights into how the nucleus is organized and functions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28905911"}, {"offsetInBeginSection": 246, "offsetInEndSection": 470, "text": "The project will develop and benchmark experimental and computational approaches for measuring genome conformation and nuclear organization, and investigate how these contribute to gene regulation and other genome functions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28905911"}, {"offsetInBeginSection": 0, "offsetInEndSection": 37, "text": "Corrigendum: The 4D nucleome project.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29168505"}]}, {"id": "5a8b1264fcd1d6a10c00001d", "body": "Fusarium oxysporum f. sp lycopersici. is a plant pathogen in plants producing what common food?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10517025", "http://www.ncbi.nlm.nih.gov/pubmed/24561899", "http://www.ncbi.nlm.nih.gov/pubmed/18945093", "http://www.ncbi.nlm.nih.gov/pubmed/18944618", "http://www.ncbi.nlm.nih.gov/pubmed/18624637", "http://www.ncbi.nlm.nih.gov/pubmed/24909710", "http://www.ncbi.nlm.nih.gov/pubmed/18943589", "http://www.ncbi.nlm.nih.gov/pubmed/24024636", "http://www.ncbi.nlm.nih.gov/pubmed/9237400", "http://www.ncbi.nlm.nih.gov/pubmed/28956188"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 41, "text": "Tomatinase from Fusarium oxysporum f. sp.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025"}, {"offsetInBeginSection": 42, "offsetInEndSection": 89, "text": "lycopersici defines a new class of saponinases.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025"}, {"offsetInBeginSection": 198, "offsetInEndSection": 223, "text": "Fusarium oxysporum f. sp.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025"}, {"offsetInBeginSection": 224, "offsetInEndSection": 382, "text": "lycopersici and other tomato pathogens produce extracellular enzymes known as tomatinases, which deglycosylate alpha-tomatine to yield less toxic derivatives.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025"}, {"offsetInBeginSection": 383, "offsetInEndSection": 517, "text": "We have cloned and characterized the cDNA and genomic DNA encoding tomatinase from the vascular pathogen of tomato F. oxysporum f. sp.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025"}, {"offsetInBeginSection": 1027, "offsetInEndSection": 1062, "text": "Tomatinase from F. oxysporum f. sp.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025"}, {"offsetInBeginSection": 1063, "offsetInEndSection": 1149, "text": "lycopersici is encoded by a single gene whose expression is induced by alpha-tomatine.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025"}, {"offsetInBeginSection": 1333, "offsetInEndSection": 1458, "text": "The tomatinase gene is expressed in planta in both roots and stems throughout the entire disease cycle of F. oxysporum f. sp.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "In vitro antifugal activity of medicinal plant extract against Fusarium oxysporum f. sp.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24561899"}, {"offsetInBeginSection": 89, "offsetInEndSection": 140, "text": "lycopersici race 3 the causal agent of tomato wilt.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24561899"}]}, {"id": "5a70d43b99e2c3af26000003", "body": "Does prolactinoma increase osteoporosis risk?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11293923", "http://www.ncbi.nlm.nih.gov/pubmed/20205855", "http://www.ncbi.nlm.nih.gov/pubmed/22553947", "http://www.ncbi.nlm.nih.gov/pubmed/17578827", "http://www.ncbi.nlm.nih.gov/pubmed/26319389"], "snippets": [{"offsetInBeginSection": 1145, "offsetInEndSection": 1323, "text": "The relative risk for developing osteoporosis in women with prolactinoma was found to be 4.5, indicating that hyperprolactinemia in women is a major risk factor for osteoporosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11293923"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Effects of hyperprolactinemia on osteoporotic fracture risk in premenopausal women.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11293923"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Prolactinoma presenting as chronic anaemia with osteoporosis: a case report.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205855"}, {"offsetInBeginSection": 154, "offsetInEndSection": 249, "text": "Six years later, he was evaluated and diagnosed with a prolactinoma and resultant osteoporosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205855"}, {"offsetInBeginSection": 250, "offsetInEndSection": 378, "text": "Prolactinoma in old people may present insidiously with chronic anaemia and osteoporosis with or without sexual dysfunction.CASE", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205855"}, {"offsetInBeginSection": 379, "offsetInEndSection": 491, "text": "PRESENTATION: We describe the case of a 70-year-old Caucasian man who presented with mild anaemia and tiredness.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205855"}, {"offsetInBeginSection": 838, "offsetInEndSection": 999, "text": "His serum prolactin was massively increased and a magnetic resonance imaging (MRI) scan of the head demonstrated a pituitary mass consistent with a prolactinoma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205855"}, {"offsetInBeginSection": 1000, "offsetInEndSection": 1048, "text": "Dual X-ray absorptiometry revealed osteoporosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205855"}, {"offsetInBeginSection": 1049, "offsetInEndSection": 1169, "text": "Treatment of the prolactinoma led to a reduction in his serum prolactin with a rise in his haemoglobin to normal levels.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205855"}, {"offsetInBeginSection": 1170, "offsetInEndSection": 1284, "text": "This suggested that the prolactinoma was present during the initial presentation and was the cause of his anaemia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205855"}]}, {"id": "5a6fa31ab750ff445500005e", "body": "Which method has been developed for assignment of enhancers to target genes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29070071"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "McEnhancer: predicting gene expression via semi-supervised assignment of enhancers to target genes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29070071"}, {"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Transcriptional enhancers regulate spatio-temporal gene expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29070071"}, {"offsetInBeginSection": 68, "offsetInEndSection": 177, "text": "While genomic assays can identify putative enhancers en masse, assigning target genes is a complex challenge.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29070071"}, {"offsetInBeginSection": 178, "offsetInEndSection": 393, "text": "We devised a machine learning approach, McEnhancer, which links target genes to putative enhancers via a semi-supervised learning algorithm that predicts gene expression patterns based on enriched sequence features.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29070071"}, {"offsetInBeginSection": 611, "offsetInEndSection": 752, "text": "Our model provides a general framework to link globally identified enhancers to targets and contributes to deciphering the regulatory genome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29070071"}]}, {"id": "5a8dc6b4fcd1d6a10c000026", "body": "List 2 approved drug treatments for Inflammatory Bowel Disease (IBD).", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27753694", "http://www.ncbi.nlm.nih.gov/pubmed/23051720", "http://www.ncbi.nlm.nih.gov/pubmed/21936033", "http://www.ncbi.nlm.nih.gov/pubmed/27570643", "http://www.ncbi.nlm.nih.gov/pubmed/21484967", "http://www.ncbi.nlm.nih.gov/pubmed/17129810", "http://www.ncbi.nlm.nih.gov/pubmed/25685145", "http://www.ncbi.nlm.nih.gov/pubmed/17461487", "http://www.ncbi.nlm.nih.gov/pubmed/28868386", "http://www.ncbi.nlm.nih.gov/pubmed/26631943"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Drug Repositioning in Inflammatory Bowel Disease Based on Genetic Information.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "BACKGROUND: Currently, 200 genetic risk loci have been identified for inflammatory bowel disease (IBD).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694"}, {"offsetInBeginSection": 316, "offsetInEndSection": 423, "text": "Our aim was to use genetic knowledge to identify drugs that warrant further investigation in IBD treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694"}, {"offsetInBeginSection": 423, "offsetInEndSection": 596, "text": "METHODS: We hypothesized that proteins encoded by IBD candidate genes are potential IBD drug targets because genetic information can increase successful drug identification.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694"}, {"offsetInBeginSection": 802, "offsetInEndSection": 935, "text": "Promising potential IBD drugs were selected based on a manual literature search of all identified drugs (PubMed, ClinicalTrials.gov).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694"}, {"offsetInBeginSection": 935, "offsetInEndSection": 1021, "text": "RESULTS: We have identified 113 drugs that could potentially be used in IBD treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694"}, {"offsetInBeginSection": 1277, "offsetInEndSection": 1385, "text": "CONCLUSIONS: We confirm that proteins encoded by IBD candidate genes are targeted by approved IBD therapies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694"}, {"offsetInBeginSection": 1506, "offsetInEndSection": 1602, "text": "We also identify investigational new drugs that warrant further investigation for IBD treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694"}, {"offsetInBeginSection": 1603, "offsetInEndSection": 1750, "text": "Incorporating this process in IBD drug development will improve the utilization of genetic data and could lead to the improvement of IBD treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694"}, {"offsetInBeginSection": 0, "offsetInEndSection": 51, "text": "First-line therapies in inflammatory bowel disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23051720"}]}, {"id": "5a70e4b399e2c3af26000008", "body": "Glecaprevir and Pibrentasvir are used for tratment of which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28688001", "http://www.ncbi.nlm.nih.gov/pubmed/28800195", "http://www.ncbi.nlm.nih.gov/pubmed/28807904", "http://www.ncbi.nlm.nih.gov/pubmed/28412293", "http://www.ncbi.nlm.nih.gov/pubmed/29020583", "http://www.ncbi.nlm.nih.gov/pubmed/28818546"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Pharmacokinetic Interactions and Safety of Coadministration of Glecaprevir and Pibrentasvir in Healthy Volunteers.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28688001"}, {"offsetInBeginSection": 15, "offsetInEndSection": 160, "text": "OBJECTIVE: Glecaprevir and pibrentasvir are pangenotypic direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28688001"}, {"offsetInBeginSection": 161, "offsetInEndSection": 314, "text": "The aim of the present study was to evaluate the drug-drug interaction and safety of glecaprevir and pibrentasvir coadministration in healthy volunteers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28688001"}, {"offsetInBeginSection": 556, "offsetInEndSection": 765, "text": "Intensive blood sampling was performed on Days 1, 7, 8, and 14, and pharmacokinetic interactions were assessed using a repeated measures analysis of glecaprevir and pibrentasvir maximum plasma concentration (C", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28688001"}, {"offsetInBeginSection": 766, "offsetInEndSection": 865, "text": "RESULTS: Coadministration of glecaprevir 400\u00a0mg increased pibrentasvir 120 and 40\u00a0mg steady-state C", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28688001"}, {"offsetInBeginSection": 866, "offsetInEndSection": 1126, "text": "CONCLUSIONS: Coadministration of pibrentasvir 120\u00a0mg with glecaprevir doses up to 400\u00a0mg resulted in increases in pibrentasvir exposures without significant changes in glecaprevir exposures in the absence of any clinically significant laboratory abnormalities.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28688001"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800195"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "Glecaprevir and pibrentasvir are direct-acting antiviral agents being developed as combination therapy for the treatment of chronic hepatitis C virus infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800195"}, {"offsetInBeginSection": 161, "offsetInEndSection": 391, "text": "The aim of the present studies was to assess the effect of race and ethnicity (white, Han Chinese, Japanese) on the pharmacokinetics and safety of multiple oral doses of glecaprevir and pibrentasvir given alone and in combination.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800195"}, {"offsetInBeginSection": 555, "offsetInEndSection": 775, "text": "Glecaprevir (100, 200, 300, or 700\u00a0mg once daily) and pibrentasvir (80, 120, or 160\u00a0mg once daily) were administered alone for 7 days followed by the combination of both direct-acting antiviral agents for another 7 days.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800195"}]}, {"id": "5a6fa417b750ff445500005f", "body": "Describe the RNA Centric Annotation System (RCAS)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28334930"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "RCAS: an RNA centric annotation system for transcriptome-wide regions of interest.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930"}, {"offsetInBeginSection": 288, "offsetInEndSection": 536, "text": "Here, we present the RNA Centric Annotation System (RCAS), an R package, which is designed to ease the process of creating gene-centric annotations and analysis for the genomic regions of interest obtained from various RNA-based omics technologies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930"}, {"offsetInBeginSection": 661, "offsetInEndSection": 798, "text": "RCAS is an R/Bioconductor package but we also created graphical user interfaces including a Galaxy wrapper and a stand-alone web service.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930"}, {"offsetInBeginSection": 799, "offsetInEndSection": 965, "text": "The application of RCAS on published datasets shows that RCAS is not only able to reproduce published findings but also helps generate novel knowledge and hypotheses.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930"}, {"offsetInBeginSection": 966, "offsetInEndSection": 1207, "text": "The meta-gene profiles, gene-centric annotation, motif analysis and gene-set analysis provided by RCAS provide contextual knowledge which is necessary for understanding the functional aspects of different biological events that involve RNAs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930"}, {"offsetInBeginSection": 1337, "offsetInEndSection": 1449, "text": "RCAS is available at http://bioconductor.org/packages/release/bioc/html/RCAS.html and http://rcas.mdc-berlin.de.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930"}]}, {"id": "5a76018c83b0d9ea6600000e", "body": "List the ten types of conjoined twins.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/1412053", "http://www.ncbi.nlm.nih.gov/pubmed/24193193", "http://www.ncbi.nlm.nih.gov/pubmed/8787375", "http://www.ncbi.nlm.nih.gov/pubmed/12483645", "http://www.ncbi.nlm.nih.gov/pubmed/29064095", "http://www.ncbi.nlm.nih.gov/pubmed/19060714", "http://www.ncbi.nlm.nih.gov/pubmed/16122113", "http://www.ncbi.nlm.nih.gov/pubmed/19361646", "http://www.ncbi.nlm.nih.gov/pubmed/16677900", "http://www.ncbi.nlm.nih.gov/pubmed/27369817"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 47, "text": "Conjoined twins: theoretical embryologic basis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1412053"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "A theoretical basis for the embryology of conjoined twins was formulated from clinical experience with ten cases and extensive review of pertinent embryologic and clinical literature, including over 500 cases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1412053"}, {"offsetInBeginSection": 210, "offsetInEndSection": 421, "text": "Regarding the age old question of fusion or fission, it is concluded that there is no known embryologic process by which conjoined twins can be formed by fission but firm evidence to support fusion in all cases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1412053"}, {"offsetInBeginSection": 547, "offsetInEndSection": 703, "text": "Intact ectoderm will not fuse to intact ectoderm, and all seven types of conjoined twins are explained by seven possible sites of union in the early embryo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1412053"}, {"offsetInBeginSection": 876, "offsetInEndSection": 1344, "text": "These anterolaterally united parapagus twins must result from two nearly parallel notochords in close proximity; craniopagi and pygopagi from fusion at the cranial and caudal neuropores, respectively; cephalopagi and ischiopagi from union at the pharyngeal and cloacal membranes, respectively; thoracopagi from merging of the cardiac anlage; and omphalopagi from fusion of the umbilicus or of the edges of two embryonic discs in any area not including the above sites.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1412053"}, {"offsetInBeginSection": 1479, "offsetInEndSection": 1665, "text": "The rarity of cases (2) not easily explained by the above theories, and the nearly 6% of twins with two umbilical cords arising from the placenta would seem to support these conclusions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1412053"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "Diagnostic techniques and criteria for first-trimester conjoined twin documentation: a review of the literature illustrated by three recent cases.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193193"}, {"offsetInBeginSection": 0, "offsetInEndSection": 37, "text": "OBJECTIVES: Conjoined twins are rare.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193193"}, {"offsetInBeginSection": 405, "offsetInEndSection": 553, "text": "DESIGN: A PubMed literature search was performed using the terms ultrasound, Doppler, MRI, and CT combined with first-trimester and conjoined twins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193193"}, {"offsetInBeginSection": 670, "offsetInEndSection": 792, "text": "RESULTS: The different types of conjoined twins are summarized in a table for practical use during ultrasound examination.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193193"}]}, {"id": "5a70e6e899e2c3af26000009", "body": "What is the mechanism of action of Fremanezumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28972120", "http://www.ncbi.nlm.nih.gov/pubmed/28642283"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (A\u03b4) But Not Unmyelinated (C) Meningeal Nociceptors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120"}, {"offsetInBeginSection": 0, "offsetInEndSection": 220, "text": "Calcitonin gene-related peptide (CGRP), the most abundant neuropeptide in primary afferent sensory neurons, is strongly implicated in the pathophysiology of migraine headache, but its role in migraine is still equivocal.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120"}, {"offsetInBeginSection": 221, "offsetInEndSection": 451, "text": "As a new approach to migraine treatment, humanized anti-CGRP monoclonal antibodies (CGRP-mAbs) were developed to reduce the availability of CGRP, and were found effective in reducing the frequency of chronic and episodic migraine.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120"}, {"offsetInBeginSection": 452, "offsetInEndSection": 741, "text": "We recently tested the effect of fremanezumab (TEV-48125), a CGRP-mAb, on the activity of second-order trigeminovascular dorsal horn neurons that receive peripheral input from the cranial dura, and found a selective inhibition of high-threshold but not wide-dynamic range class of neurons.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120"}, {"offsetInBeginSection": 742, "offsetInEndSection": 1128, "text": "To investigate the basis for this selective inhibitory effect, and further explore the mechanism of action of CGRP-mAbs, we tested the effect of fremanezumab on the cortical spreading depression-evoked activation of mechanosensitive primary afferent meningeal nociceptors that innervate the cranial dura, using single-unit recording in the trigeminal ganglion of anesthetized male rats.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120"}, {"offsetInBeginSection": 1129, "offsetInEndSection": 1348, "text": "Fremanezumab pretreatment selectively inhibited the responsiveness of A\u03b4 neurons, but not C-fiber neurons, as reflected in a decrease in the percentage of neurons that showed activation by cortical spreading depression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120"}, {"offsetInBeginSection": 1349, "offsetInEndSection": 1471, "text": "These findings identify A\u03b4 meningeal nociceptors as a likely site of action of fremanezumab in the prevention of headache.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120"}, {"offsetInBeginSection": 1472, "offsetInEndSection": 1773, "text": "The selectivity in its peripheral inhibitory action may partly account for fremanezumab's selective inhibition of high-threshold, as a result of a predominant A-\u03b4 input to high-threshold neurons, but not wide dynamic-range dorsal horn neurons, and why it may not be effective in all migraine patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Selective Inhibition of Trigeminovascular Neurons by Fremanezumab: A Humanized Monoclonal Anti-CGRP Antibody.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28642283"}, {"offsetInBeginSection": 282, "offsetInEndSection": 439, "text": "Recently, a new class of such drugs, humanized anti-CGRP monoclonal antibodies (CGRP-mAbs), were found to be effective in reducing the frequency of migraine.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28642283"}]}, {"id": "5a6fa61ab750ff4455000060", "body": "Which tool exists for microsatellite (SSR) loci detection and primer design?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27366148"], "snippets": [{"offsetInBeginSection": 4, "offsetInEndSection": 51, "text": "SSR: Microsatellite Finder and Primer Designer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148"}, {"offsetInBeginSection": 150, "offsetInEndSection": 278, "text": "FullSSR is a new bioinformatic tool for microsatellite (SSR) loci detection and primer design using genomic data from NGS assay.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148"}, {"offsetInBeginSection": 578, "offsetInEndSection": 653, "text": "FullSSR performance was compared against other similar SSR search programs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148"}, {"offsetInBeginSection": 849, "offsetInEndSection": 926, "text": "FullSSR simplifies the detection of SSRs and primer design on a big data set.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148"}]}, {"id": "5a70e88699e2c3af2600000a", "body": "Describe mechanism of action of Nusinersen.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27939059", "http://www.ncbi.nlm.nih.gov/pubmed/28884620"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "BACKGROUND: Nusinersen is a 2'-O-methoxyethyl phosphorothioate-modified antisense drug being developed to treat spinal muscular atrophy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059"}, {"offsetInBeginSection": 137, "offsetInEndSection": 346, "text": "Nusinersen is specifically designed to alter splicing of SMN2 pre-mRNA and thus increase the amount of functional survival motor neuron (SMN) protein that is deficient in patients with spinal muscular atrophy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059"}, {"offsetInBeginSection": 346, "offsetInEndSection": 625, "text": "METHODS: This open-label, phase 2, escalating dose clinical study assessed the safety and tolerability, pharmacokinetics, and clinical efficacy of multiple intrathecal doses of nusinersen (6 mg and 12 mg dose equivalents) in patients with infantile-onset spinal muscular atrophy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059"}, {"offsetInBeginSection": 626, "offsetInEndSection": 835, "text": "Eligible participants were of either gender aged between 3 weeks and 7 months old with onset of spinal muscular atrophy symptoms between 3 weeks and 6 months, who had SMN1 homozygous gene deletion or mutation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059"}, {"offsetInBeginSection": 836, "offsetInEndSection": 1022, "text": "Safety assessments included adverse events, physical and neurological examinations, vital signs, clinical laboratory tests, cerebrospinal fluid laboratory tests, and electrocardiographs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059"}, {"offsetInBeginSection": 1023, "offsetInEndSection": 1390, "text": "Clinical efficacy assessments included event free survival, and change from baseline of two assessments of motor function: the motor milestones portion of the Hammersmith Infant Neurological Exam-Part 2 (HINE-2) and the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) motor function test, and compound motor action potentials.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059"}, {"offsetInBeginSection": 1493, "offsetInEndSection": 1632, "text": "HINE-2, CHOP-INTEND, and compound motor action potential were compared between baseline and last visit using the Wilcoxon signed-rank test.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059"}, {"offsetInBeginSection": 2207, "offsetInEndSection": 2422, "text": "INTERPRETATION: Administration of multiple intrathecal doses of nusinersen showed acceptable safety and tolerability, pharmacology consistent with its intended mechanism of action, and encouraging clinical efficacy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059"}, {"offsetInBeginSection": 2423, "offsetInEndSection": 2563, "text": "Results informed the design of an ongoing, sham-controlled, phase 3 clinical study of nusinersen in infantile-onset spinal muscular atrophy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059"}]}, {"id": "5a6fa9f7b750ff4455000061", "body": "Describe Click-PEGylation", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28366801", "http://www.ncbi.nlm.nih.gov/pubmed/22988919", "http://www.ncbi.nlm.nih.gov/pubmed/18590303", "http://www.ncbi.nlm.nih.gov/pubmed/28205176", "http://www.ncbi.nlm.nih.gov/pubmed/27213717", "http://www.ncbi.nlm.nih.gov/pubmed/23106398", "http://www.ncbi.nlm.nih.gov/pubmed/22243664", "http://www.ncbi.nlm.nih.gov/pubmed/23613182", "http://www.ncbi.nlm.nih.gov/pubmed/21618993", "http://www.ncbi.nlm.nih.gov/pubmed/9279893"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Click-PEGylation - A mobility shift approach to assess the redox state of cysteines in candidate proteins.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28366801"}, {"offsetInBeginSection": 1551, "offsetInEndSection": 1856, "text": "To establish a more robust method for redox-selective PEGylation, we have utilised a Click chemistry approach, where free thiol groups are first labelled with a reagent modified to contain an alkyne moiety, which is subsequently Click-reacted with a PEG molecule containing a complementary azide function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28366801"}, {"offsetInBeginSection": 2068, "offsetInEndSection": 2171, "text": "Here we show how the Click-PEGylation technique can be used to interrogate the redox state of proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28366801"}, {"offsetInBeginSection": 381, "offsetInEndSection": 612, "text": "To this end, we describe the development of copper-catalyzed azide-alkyne cycloaddition (CuAAC, a click chemistry reaction) for site-specific PEGylation of interferon \u03b2-1b (IFNb) containing azidohomoalanine (Aha) at the N-terminus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22988919"}, {"offsetInBeginSection": 0, "offsetInEndSection": 51, "text": "PEGylation of porous silicon using click chemistry.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18590303"}, {"offsetInBeginSection": 159, "offsetInEndSection": 250, "text": "In this work, we investigate the PEGylation of porous silicon wafers using click chemistry.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18590303"}, {"offsetInBeginSection": 566, "offsetInEndSection": 747, "text": "This work highlights the simplicity of click-chemistry-based functionalization in tailoring the porous silicon surface chemistry and controlling protein-porous silicon interactions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18590303"}, {"offsetInBeginSection": 506, "offsetInEndSection": 894, "text": "Using scanning cysteine mutagenesis, followed by PEGylation, one can map the accessibility of the introduced cysteines, hence inferring the membrane topology of the protein.We used PEGylation to determine the membrane topology of the sterol regulatory domain of a cholesterol synthesis enzyme, squalene monooxygenase, identifying that it is anchored to the membrane via a re-entrant loop.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28205176"}, {"offsetInBeginSection": 252, "offsetInEndSection": 456, "text": "In an effort to develop new enabling technologies to integrate bioprocessing and protein modification, we describe the use of disulfide-bridging conjugation to conduct PEGylation during protein refolding.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27213717"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Protein PEGylation (attaching PEG chains to proteins) has been widely used in pharmaceuticals and nanotechnology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23106398"}]}, {"id": "5a70ea8299e2c3af2600000b", "body": "Does Evolocumab improve cognitive function?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28207168", "http://www.ncbi.nlm.nih.gov/pubmed/28813214"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 340, "text": "Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28207168"}, {"offsetInBeginSection": 388, "offsetInEndSection": 680, "text": "Patients with prior cardiovascular disease treated with maximally tolerated statin enrolled in FOURIER (the randomized, double-blind, placebo-controlled cardiovascular outcome study of the PCSK9i evolocumab) could participate in this prospective assessment of cognitive function (EBBINGHAUS).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28207168"}, {"offsetInBeginSection": 821, "offsetInEndSection": 1092, "text": "Cognitive testing was performed using the Cambridge Neuropsychological Test Automated Battery, a tablet-based tool assessing executive function, working memory, memory function, and psychomotor speed at baseline, weeks 24 and 48, every 48 weeks thereafter, and study end.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28207168"}, {"offsetInBeginSection": 1187, "offsetInEndSection": 1314, "text": "The primary hypothesis was that evolocumab would be noninferior to placebo in the mean change from baseline over time in SWMSI.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28207168"}, {"offsetInBeginSection": 0, "offsetInEndSection": 55, "text": "Cognitive Function in a Randomized Trial of Evolocumab.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813214"}, {"offsetInBeginSection": 0, "offsetInEndSection": 275, "text": "Background Findings from clinical trials of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have led to concern that these drugs or the low levels of low-density lipoprotein (LDL) cholesterol that result from their use are associated with cognitive deficits.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813214"}, {"offsetInBeginSection": 276, "offsetInEndSection": 500, "text": "Methods In a subgroup of patients from a randomized, placebo-controlled trial of evolocumab added to statin therapy, we prospectively assessed cognitive function using the Cambridge Neuropsychological Test Automated Battery.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813214"}, {"offsetInBeginSection": 1037, "offsetInEndSection": 1144, "text": "Assessments of cognitive function were performed at baseline, week 24, yearly, and at the end of the trial.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813214"}, {"offsetInBeginSection": 1145, "offsetInEndSection": 1489, "text": "The primary analysis was a noninferiority comparison of the mean change from baseline in the score on the spatial working memory strategy index of executive function between the patients who received evolocumab and those who received placebo; the noninferiority margin was set at 20% of the standard deviation of the score in the placebo group.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813214"}]}, {"id": "5a75dff883b0d9ea66000003", "body": "Name curated data resources for ChIP-seq data", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27789702", "http://www.ncbi.nlm.nih.gov/pubmed/26969372", "http://www.ncbi.nlm.nih.gov/pubmed/22495751", "http://www.ncbi.nlm.nih.gov/pubmed/24253304", "http://www.ncbi.nlm.nih.gov/pubmed/28529706", "http://www.ncbi.nlm.nih.gov/pubmed/29069466", "http://www.ncbi.nlm.nih.gov/pubmed/19892823", "http://www.ncbi.nlm.nih.gov/pubmed/21097880", "http://www.ncbi.nlm.nih.gov/pubmed/22827163", "http://www.ncbi.nlm.nih.gov/pubmed/27863463"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Cistrome Data Browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27789702"}, {"offsetInBeginSection": 0, "offsetInEndSection": 235, "text": "Chromatin immunoprecipitation, DNase I hypersensitivity and transposase-accessibility assays combined with high-throughput sequencing enable the genome-wide study of chromatin dynamics, transcription factor binding and gene regulation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27789702"}, {"offsetInBeginSection": 236, "offsetInEndSection": 527, "text": "Although rapidly accumulating publicly available ChIP-seq, DNase-seq and ATAC-seq data are a valuable resource for the systematic investigation of gene regulation processes, a lack of standardized curation, quality control and analysis procedures have hindered extensive reuse of these data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27789702"}, {"offsetInBeginSection": 528, "offsetInEndSection": 751, "text": "To overcome this challenge, we built the Cistrome database, a collection of ChIP-seq and chromatin accessibility data (DNase-seq and ATAC-seq) published before January 1, 2016, including 13 366 human and 9953 mouse samples.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27789702"}, {"offsetInBeginSection": 752, "offsetInEndSection": 901, "text": "All the data have been carefully curated and processed with a streamlined analysis pipeline and evaluated with comprehensive quality control metrics.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27789702"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Integrating RNA-seq and ChIP-seq data to characterize long non-coding RNAs in Drosophila melanogaster.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26969372"}, {"offsetInBeginSection": 528, "offsetInEndSection": 695, "text": "Moreover, there is an increasing interest in the use of ChIP-seq data (H3K4me3, H3K36me3 and Pol II) to detect signatures of active transcription for reported lncRNAs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26969372"}, {"offsetInBeginSection": 695, "offsetInEndSection": 879, "text": "RESULTS: We have developed a computational approach to identify new lncRNAs from two tissue-specific RNA-seq datasets using the poly(A)-enriched and the ribo-zero method, respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26969372"}, {"offsetInBeginSection": 1032, "offsetInEndSection": 1312, "text": "We then utilized 61 RNA-seq and 32 ChIP-seq datasets to improve the annotation of the curated lncRNAs with regards to transcriptional direction, exon regions, classification, expression in the brain, possession of a poly(A) tail, and presence of conventional chromatin signatures.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26969372"}, {"offsetInBeginSection": 1313, "offsetInEndSection": 1483, "text": "Furthermore, we used 30 time-course RNA-seq datasets and 32 ChIP-seq datasets to investigate whether the lncRNAs reported by RNA-seq have active transcription signatures.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26969372"}]}, {"id": "5a72284b2dc08e987e000001", "body": "Can radius fracture cause carpal tunnel syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29169594", "http://www.ncbi.nlm.nih.gov/pubmed/23026468", "http://www.ncbi.nlm.nih.gov/pubmed/21786553", "http://www.ncbi.nlm.nih.gov/pubmed/21505639", "http://www.ncbi.nlm.nih.gov/pubmed/26566562", "http://www.ncbi.nlm.nih.gov/pubmed/27454517", "http://www.ncbi.nlm.nih.gov/pubmed/11514776"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 51, "text": "Carpal Tunnel Syndrome and Distal Radius Fractures.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29169594"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Carpal tunnel syndrome (CTS) after distal radius fractures can present in 3 forms: acute, transient, and delayed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29169594"}, {"offsetInBeginSection": 114, "offsetInEndSection": 167, "text": "Acute CTS requires an emergent carpal tunnel release.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29169594"}, {"offsetInBeginSection": 168, "offsetInEndSection": 313, "text": "Many patients with transient CTS after distal radius fracture do not require surgical release of the carpal tunnel once the fracture is repaired.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29169594"}, {"offsetInBeginSection": 314, "offsetInEndSection": 441, "text": "Prophylactic carpal tunnel release in the absence of signs and symptoms of CTS after a distal radius fracture is not indicated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29169594"}, {"offsetInBeginSection": 442, "offsetInEndSection": 600, "text": "For patients with delayed CTS after a distal radius fracture, all possible causes of nerve compression should be considered and addressed in standard fashion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29169594"}, {"offsetInBeginSection": 0, "offsetInEndSection": 52, "text": "Carpal tunnel syndrome after distal radius fracture.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026468"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Carpal tunnel syndrome is a common condition and is a well-recognized phenomenon following a distal radius fracture.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026468"}, {"offsetInBeginSection": 193, "offsetInEndSection": 329, "text": "If acute carpal tunnel syndrome is noted, then surgical release of the carpal tunnel and fracture fixation should be performed urgently.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026468"}, {"offsetInBeginSection": 330, "offsetInEndSection": 464, "text": "If early carpal tunnel syndrome findings are noted during distal radius fracture management, all potential causes should be evaluated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026468"}]}, {"id": "5a75f1f383b0d9ea66000006", "body": "Can Logic Alignment Free (LAF) be used for bacterial genomes classification?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26664519"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "LAF: Logic Alignment Free and its application to bacterial genomes classification.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "Alignment-free algorithms can be used to estimate the similarity of biological sequences and hence are often applied to the phylogenetic reconstruction of genomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519"}, {"offsetInBeginSection": 315, "offsetInEndSection": 511, "text": "In this paper, we present Logic Alignment Free (LAF), a method that combines alignment-free techniques and rule-based classification algorithms in order to assign biological samples to their taxa.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519"}, {"offsetInBeginSection": 512, "offsetInEndSection": 689, "text": "This method searches for a minimal subset of k-mers whose relative frequencies are used to build classification models as disjunctive-normal-form logic formulas (if-then rules).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519"}, {"offsetInBeginSection": 690, "offsetInEndSection": 791, "text": "We apply LAF successfully to the classification of bacterial genomes to their corresponding taxonomy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519"}, {"offsetInBeginSection": 792, "offsetInEndSection": 970, "text": "In particular, we succeed in obtaining reliable classification at different taxonomic levels by extracting a handful of rules, each one based on the frequency of just few k-mers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519"}, {"offsetInBeginSection": 971, "offsetInEndSection": 1235, "text": "State of the art methods to adjust the frequency of k-mers to the character distribution of the underlying genomes have negligible impact on classification performance, suggesting that the signal of each class is strong and that LAF is effective in identifying it.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519"}]}, {"id": "5a722a052dc08e987e000002", "body": "Is Marfan syndrome associated with chordal rupture?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10441700", "http://www.ncbi.nlm.nih.gov/pubmed/14658812", "http://www.ncbi.nlm.nih.gov/pubmed/7790334", "http://www.ncbi.nlm.nih.gov/pubmed/18172522", "http://www.ncbi.nlm.nih.gov/pubmed/17317544"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Acute mitral regurgitation due to chordal rupture in a patient with neonatal Marfan syndrome caused by a deletion in exon 29 of the FBN1 gene.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10441700"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "The neonatal Marfan syndrome is an autosomal dominantly inherited disease with an extremely poor prognosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10441700"}, {"offsetInBeginSection": 315, "offsetInEndSection": 432, "text": "The infant died at the age of 3 months due to severe acute mitral regurgitation leading to intractable heart failure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10441700"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Surgical management of mitral regurgitation in patients with Marfan syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14658812"}, {"offsetInBeginSection": 26, "offsetInEndSection": 257, "text": "STUDY: Although, in patients with Marfan syndrome, the most common cardiovascular abnormalities are aortic root dilatation and aortic valve regurgitation, mitral valve dysfunction is the most frequently accompanying cardiac lesion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14658812"}, {"offsetInBeginSection": 257, "offsetInEndSection": 479, "text": "METHODS: The clinical course and management is reported of nine patients (seven men, two women; mean age 29.2 +/- 2.3 years) with Marfan syndrome who required different mitral valve procedures and aortic valve replacement.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14658812"}, {"offsetInBeginSection": 480, "offsetInEndSection": 639, "text": "Mitral regurgitation was caused by annulus dilatation in all patients, by leaflet prolapse in five patients, and by chordal rupture due to endocarditis in two.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14658812"}, {"offsetInBeginSection": 640, "offsetInEndSection": 770, "text": "Six patients underwent mitral valve replacement; three of these were operated on using preservation of the mitral valve apparatus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14658812"}, {"offsetInBeginSection": 771, "offsetInEndSection": 839, "text": "Three patients underwent mitral annuloplasty and chordal shortening.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14658812"}, {"offsetInBeginSection": 1103, "offsetInEndSection": 1403, "text": "CONCLUSION: This experience in mitral valve procedures indicated that the connective tissue defect might compromise the results of such surgery, but that mitral valve operations could be performed satisfactorily in young Marfan syndrome patients, despite complications of left ventricular dilatation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14658812"}]}, {"id": "5a75f2fc83b0d9ea66000007", "body": "What is TCGA2BED?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28049410"], "snippets": []}, {"id": "5a722ccd2dc08e987e000003", "body": "What is the mechanism of action of Tezepelumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28877011"], "snippets": []}, {"id": "5a75f5aa83b0d9ea66000008", "body": "Describe JACUSA", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28049429"], "snippets": [{"offsetInBeginSection": 866, "offsetInEndSection": 1027, "text": "RESULTS: We present JACUSA, a versatile one-stop solution to detect single nucleotide variant positions from comparing RNA-DNA and/or RNA-RNA sequencing samples.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429"}, {"offsetInBeginSection": 1028, "offsetInEndSection": 1147, "text": "The performance of JACUSA has been carefully evaluated and compared to other variant callers in an in silico benchmark.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429"}, {"offsetInBeginSection": 1148, "offsetInEndSection": 1275, "text": "JACUSA outperforms other algorithms in terms of the F measure, which combines precision and recall, in all benchmark scenarios.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429"}, {"offsetInBeginSection": 1276, "offsetInEndSection": 1347, "text": "This performance margin is highest for the RNA-RNA comparison scenario.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429"}, {"offsetInBeginSection": 1348, "offsetInEndSection": 1564, "text": "We further validated JACUSA's performance by testing its ability to detect A\u2192I events using sequencing data from a human cell culture experiment and publicly available RNA-seq data from Drosophila melanogaster heads.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429"}, {"offsetInBeginSection": 1707, "offsetInEndSection": 1827, "text": "JACUSA has a higher recall and comparable precision for detecting true editing sites in RDD comparisons of HEK-293 data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429"}, {"offsetInBeginSection": 1828, "offsetInEndSection": 1964, "text": "Intriguingly, JACUSA captures most A\u2192I events from RRD comparisons of RNA sequencing data derived from Drosophila and HEK-293 data sets.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429"}, {"offsetInBeginSection": 1964, "offsetInEndSection": 2114, "text": "CONCLUSION: Our software JACUSA detects single nucleotide variants by comparing data from next-generation sequencing experiments (RNA-DNA or RNA-RNA).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429"}, {"offsetInBeginSection": 2115, "offsetInEndSection": 2294, "text": "In practice, JACUSA shows higher recall and comparable precision in detecting A\u2192I sites from RNA-DNA comparisons, while showing higher precision and recall in RNA-RNA comparisons.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "JACUSA: site-specific identification of RNA editing events from replicate sequencing data.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429"}]}, {"id": "5a722d9f2dc08e987e000004", "body": "What is mechanism of action of Benralizumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27119985", "http://www.ncbi.nlm.nih.gov/pubmed/27097165", "http://www.ncbi.nlm.nih.gov/pubmed/25306557", "http://www.ncbi.nlm.nih.gov/pubmed/28109128", "http://www.ncbi.nlm.nih.gov/pubmed/29086236", "http://www.ncbi.nlm.nih.gov/pubmed/28530840", "http://www.ncbi.nlm.nih.gov/pubmed/28919200", "http://www.ncbi.nlm.nih.gov/pubmed/23866823", "http://www.ncbi.nlm.nih.gov/pubmed/28737051", "http://www.ncbi.nlm.nih.gov/pubmed/25208464"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5R\u03b1, in Uncontrolled Eosinophilic Asthma.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27119985"}, {"offsetInBeginSection": 143, "offsetInEndSection": 330, "text": "Because eosinophils are key effector cells in asthmatic airway inflammation, blocking IL-5, the main cytokine responsible for its survival and activation, seems to be a rational strategy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27119985"}, {"offsetInBeginSection": 331, "offsetInEndSection": 481, "text": "While previous monoclonal antibodies against the IL-5 ligand resulted in inconsistent improvements in asthma outcomes, benralizumab has shown promise.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27119985"}, {"offsetInBeginSection": 482, "offsetInEndSection": 618, "text": "Benralizumab is a monoclonal antibody against IL-5 receptor, and has an enhanced antibody dependent cell-mediated cytotoxicity function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27119985"}, {"offsetInBeginSection": 619, "offsetInEndSection": 801, "text": "In this article, we review the theoretical advantages of benralizumab compared to previous compounds, as well as current status of the clinical development of benralizumab in asthma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27119985"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27097165"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "BACKGROUND: Airway eosinophils are considered to play an important role in the pathogenesis of asthma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27097165"}, {"offsetInBeginSection": 216, "offsetInEndSection": 328, "text": "Benralizumab is an anti-interleukin-5 receptor \u03b1 monoclonal antibody that depletes blood and airway eosinophils.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27097165"}, {"offsetInBeginSection": 452, "offsetInEndSection": 699, "text": "The primary objective was to evaluate the effect of benralizumab in adults with uncontrolled eosinophilic asthma with 2-6 incidences of exacerbations in the past year using a medium/high dose of inhaled corticosteroids and long-acting \u03b22-agonists.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27097165"}, {"offsetInBeginSection": 784, "offsetInEndSection": 924, "text": "The subjects (n = 106) were randomized into four groups: placebo (n = 27) or benralizumab 2 mg (n = 27), 20 mg (n = 26) and 100 mg (n = 26).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27097165"}]}, {"id": "5a75f6e083b0d9ea66000009", "body": "Which data simulator is available for CLIP-SEQ experiments?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26776207"], "snippets": [{"offsetInBeginSection": 5, "offsetInEndSection": 58, "text": "SIMULATOR: A DATA SIMULATOR FOR CLIP-SEQ EXPERIMENTS.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "CLIP-Seq protocols such as PAR-CLIP, HITS-CLIP or iCLIP allow a genome-wide analysis of protein-RNA interactions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207"}, {"offsetInBeginSection": 195, "offsetInEndSection": 324, "text": "Some of these tools were specifically developed for CLIP-Seq data, whereas others were designed for the analysis of RNA-Seq data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207"}, {"offsetInBeginSection": 325, "offsetInEndSection": 457, "text": "To this date, however, it has not been assessed which of the available tools are most appropriate for the analysis of CLIP-Seq data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207"}, {"offsetInBeginSection": 458, "offsetInEndSection": 582, "text": "This is because an experimental gold standard dataset on which methods can be accessed and compared, is still not available.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207"}, {"offsetInBeginSection": 583, "offsetInEndSection": 715, "text": "To address this lack of a gold-standard dataset, we here present Cseq-Simulator, a simulator for PAR-CLIP, HITS-CLIP and iCLIP-data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207"}, {"offsetInBeginSection": 846, "offsetInEndSection": 1024, "text": "In this work, we also show how Cseq-Simulator can be used to perform a comparison of steps of typical CLIP-Seq analysis pipelines, such as the read alignment or the peak calling.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207"}, {"offsetInBeginSection": 1025, "offsetInEndSection": 1150, "text": "These comparisons show which tools are useful in different settings and also allow identifying pitfalls in the data analysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207"}]}, {"id": "5a72302b2dc08e987e000005", "body": "Treatment of which disease was studied in the Gore REDUCE Clinical Study?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29090661", "http://www.ncbi.nlm.nih.gov/pubmed/28222987", "http://www.ncbi.nlm.nih.gov/pubmed/10847965", "http://www.ncbi.nlm.nih.gov/pubmed/27872317", "http://www.ncbi.nlm.nih.gov/pubmed/2940526", "http://www.ncbi.nlm.nih.gov/pubmed/26808286", "http://www.ncbi.nlm.nih.gov/pubmed/18559363", "http://www.ncbi.nlm.nih.gov/pubmed/17704480"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 250, "text": "Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: Design of the randomized Gore REDUCE Clinical Study.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29090661"}, {"offsetInBeginSection": 0, "offsetInEndSection": 249, "text": "BACKGROUND: Preliminary results in small single-center studies after stenting with the GORE TIGRIS Vascular Stent (W.\u00a0L.\u00a0Gore & Associates, Flagstaff, Ariz) show promising short-term primary patency rates, but larger, multicenter studies are needed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987"}, {"offsetInBeginSection": 250, "offsetInEndSection": 426, "text": "This study therefore investigated the performance of the GORE TIGRIS Vascular Stent at three different centers in France in patients with symptomatic peripheral artery disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987"}, {"offsetInBeginSection": 426, "offsetInEndSection": 746, "text": "METHODS: This retrospective, single-arm, multicenter cohort study included 215 patients with peripheral artery disease (Rutherford-Becker category 2-6) who were treated with the GORE TIGRIS Vascular Stent, a dual-component stent consisting of a nitinol wire frame combined with a fluoropolymer-interconnecting structure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987"}, {"offsetInBeginSection": 1036, "offsetInEndSection": 1219, "text": "RESULTS: The GORE TIGRIS Vascular Stent was used to successfully treat 239 lesions, of which 141 lesions were located in the superficial femoral artery and 98 in the popliteal artery.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987"}, {"offsetInBeginSection": 1499, "offsetInEndSection": 1732, "text": "CONCLUSIONS: Our multicenter experience with the GORE TIGRIS Vascular Stent demonstrates continued good results\u00a0at\u00a02\u00a0years for endovascular treatment of challenging obstructive superficial femoral artery and popliteal artery disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987"}, {"offsetInBeginSection": 306, "offsetInEndSection": 554, "text": "Twenty pockets were treated with Gore Resolut, a bioabsorbable membrane; 20 were treated with Gore-Tex, a titanium-reinforced membrane; and 20 with nonresorbable Gore-Tex membrane (all manufactured by Gore Regenerative Technologies, Flagstaff, AZ).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10847965"}, {"offsetInBeginSection": 1280, "offsetInEndSection": 1476, "text": "This additional evidence thus proved that treatment with bioabsorbable membranes according to GTR principles delivers not only clinical improvement, but also histological periodontal regeneration.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10847965"}, {"offsetInBeginSection": 113, "offsetInEndSection": 412, "text": "METHODS: A prospective, single-center pilot study recruited 30 symptomatic patients (mean age 64 years; 18 men) to evaluate the safety and early efficacy of the new Gore balloon-expandable covered endoprosthesis for the treatment of de novo or restenotic common and/or external iliac artery lesions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27872317"}, {"offsetInBeginSection": 1403, "offsetInEndSection": 1610, "text": "CONCLUSION: This positive first-in-human experience with the Gore balloon-expandable covered endoprosthesis suggests this device will have an important role in the management of aortoiliac occlusive disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27872317"}]}, {"id": "5a760e5583b0d9ea66000018", "body": "Which comparisons demonstrate the applicability of StereoGene in regulatory genomics?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29028265"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 257, "text": "Motivation: Genomics features with similar genome-wide distributions are generally hypothesized to be functionally related, for example, colocalization of histones and transcription start sites indicate chromatin regulation of transcription factor activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265"}, {"offsetInBeginSection": 1472, "offsetInEndSection": 1888, "text": "These analyses provide examples for the broad applicability of StereoGene for regulatory genomics.Availability and implementation: The StereoGene C\u2009++\u2009source code, program documentation, Galaxy integration scripts and examples are available from the project homepage http://stereogene.bioinf.fbb.msu.ru/.Contact: favorov@sensi.org.Supplementary information: Supplementary data are available at Bioinformatics online.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265"}]}, {"id": "5a72329e2dc08e987e000006", "body": "Falciform ligament sign is characteristic to which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23133059", "http://www.ncbi.nlm.nih.gov/pubmed/16807665", "http://www.ncbi.nlm.nih.gov/pubmed/19716250", "http://www.ncbi.nlm.nih.gov/pubmed/26577973", "http://www.ncbi.nlm.nih.gov/pubmed/2003436", "http://www.ncbi.nlm.nih.gov/pubmed/17322659", "http://www.ncbi.nlm.nih.gov/pubmed/3881894", "http://www.ncbi.nlm.nih.gov/pubmed/907474", "http://www.ncbi.nlm.nih.gov/pubmed/2910743", "http://www.ncbi.nlm.nih.gov/pubmed/27938473"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Perivascular epithelioid cell tumor (PEComa) of falciform ligament - an extremely rare tumor.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133059"}, {"offsetInBeginSection": 0, "offsetInEndSection": 60, "text": "Primary tumor of falciform ligament is exceedingly uncommon.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133059"}, {"offsetInBeginSection": 322, "offsetInEndSection": 421, "text": "Here, we report a case of PEComa of falciform ligament, which presented with a huge abdominal lump.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133059"}, {"offsetInBeginSection": 527, "offsetInEndSection": 634, "text": "On laparotomy, it was surprisingly found to arise from the falciform ligament, and this was easily removed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133059"}, {"offsetInBeginSection": 681, "offsetInEndSection": 745, "text": "There was no recurrence of disease after two years of follow up.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133059"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Falciform ligament in the management of the residual cavity for liver hydatidosis: new surgical technique.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16807665"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "INTRODUCTION: Hydatid disease is a common condition worldwide and continues to be a significant societal problem in many countries of all continents.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16807665"}, {"offsetInBeginSection": 150, "offsetInEndSection": 273, "text": "Alhough other treatment options are also available, surgery remains the cornerstone of therapy for hepatic hydatid disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16807665"}, {"offsetInBeginSection": 428, "offsetInEndSection": 617, "text": "Therefore we describe a new technique using the falciform ligament as a flap instead of omentum for managing the residual cavity, as it is more anatomic and a better option for liver cysts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16807665"}, {"offsetInBeginSection": 816, "offsetInEndSection": 1058, "text": "The falciform ligament was prepared as a flap in all patients during the initial step of the operation and, after partial cystectomy and evacuation of the cystic components, the flap was inserted into the cystic cavity and fixed with sutures.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16807665"}]}]}